Document:

Exhibit 10.1

 

 

	CONFIDENTIAL 
	Execution Version

 

TENDER AND SUPPORT AGREEMENT

 

This TENDER AND SUPPORT AGREEMENT (this
 “Agreement”), is made and entered into as of November 8, 2021, by and among Speedway Motorsports, LLC, a Delaware
limited liability company (“Parent”), Speedco II, Inc., a Delaware corporation and wholly owned subsidiary of
Parent (“Merger Sub”), and each of the Persons set forth on Schedule A hereto (each, a “Stockholder”).

 

RECITALS

 

WHEREAS,
as of the date hereof, each Stockholder is a record and beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of the
number of shares of common stock, $0.10 par value per share, of the Company (as defined below) (“Common Stock”) and
Class A common stock, $0.10 par value per share, of the Company (“Class A Stock”) set forth opposite such
Stockholder’s name on Schedule A (all such shares of Common Stock and Class A Stock set forth on Schedule A,
together with any other outstanding shares of Common Stock and Class A Stock that are hereafter issued to, or otherwise acquired
or owned, beneficially or of record, by, any Stockholder prior to the termination of this Agreement being referred to herein collectively
as, the “Shares”);

 

WHEREAS,
concurrently with the execution hereof, Parent, Merger Sub and Dover Motorsports, Inc., a Delaware corporation (the “Company”),
are entering into an Agreement and Plan of Merger (as it may be amended from time to time, the “Merger Agreement”),
which provides for, among other things, Merger Sub to commence a cash tender offer to purchase all the outstanding shares of Common Stock
and Class A Stock (the “Offer”) and, following the completion of the Offer, the merger of Merger Sub with and
into the Company (the “Merger”, and together with the Offer, the “Merger Transactions”), upon the
terms and subject to the conditions set forth in the Merger Agreement (capitalized terms used but not otherwise defined herein shall have
the respective meanings ascribed to such terms in the Merger Agreement);

 

WHEREAS,
as a condition to their willingness to enter into the Merger Agreement, Parent and Merger Sub have required that each Stockholder, and
as an inducement and in consideration therefor, each Stockholder (in such Stockholder’s capacity as a holder of Shares) has agreed
to, enter into this Agreement and tender all of the Shares as described herein.

 

AGREEMENT

 

In consideration of the foregoing and the respective
representations, warranties, covenants and agreements set forth below and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows:

 

SECTION 1

 

AGREEMENT TO TENDER AND VOTE

 

1.1
Agreement to Tender.

 

(a) Subject to the terms of this Agreement,
each Stockholder shall validly tender or cause to be tendered in the Offer all of such Stockholder’s Shares pursuant to and in accordance
with the terms of the Offer, free and clear of all Liens (other than Permitted Share Liens (as defined below)); provided, that
if the Company Board shall have effected an Adverse Recommendation Change in connection with an Intervening Event, then, for so long as
such Adverse Recommendation Change is continuing, each Stockholder shall be required to so validly tender or cause to be tendered in the
Offer not less than the number of Shares set forth opposite such Stockholder’s name under the heading “Minimum Shares”
on Schedule A.

 

    1 

     

    

 

(b) Without limiting the generality of the
foregoing, as promptly as reasonably practicable after, but in no event later than ten (10) Business Days after, the commencement
(within the meaning of Rule 14d-2 under the Exchange Act) of the Offer (or, if later, no later than three (3) Business Days
following the date of delivery of the letter of transmittal with respect to the Offer), each Stockholder shall (x) deliver pursuant
to the terms of the Offer (A) a letter of transmittal with respect to such Stockholder’s Shares or Minimum Shares, as applicable,
complying with the terms of the Offer, (B) a Certificate or Certificates (or affidavits of loss in lieu thereof) representing such
Shares or Minimum Shares, as applicable, or an “agent’s message” (or such other evidence, if any, of transfer as the
Paying Agent may reasonably request) in the case of a Book-Entry Share, and (C) all other documents or instruments required to be
delivered by stockholders of the Company generally pursuant to the terms of the Offer and/or (y) instruct such Stockholder’s
broker or such other Person that is the holder of record of any Shares or Minimum Shares, as applicable, beneficially owned by such Stockholder
to tender such Shares or Minimum Shares, as applicable, pursuant to and in accordance with this Section 1.1 and the terms
of the Offer.

 

(c) Each Stockholder agrees that, once any
of such Stockholder’s Shares are tendered, such Stockholder will not withdraw or cause to be withdrawn any of such Shares from the
Offer, unless and until this Agreement shall have been validly terminated in accordance with Section 5.2; provided,
that if an Adverse Recommendation Change is made in connection with an Intervening Event after such Stockholder has tendered its Shares,
such Stockholder may withdraw a portion of its Shares provided that such Stockholder’s Minimum Shares remain tendered and that such
Stockholder shall promptly tender such withdrawn Shares at such time that such Adverse Recommendation Change is no longer continuing.

 

1.2
Agreement to Vote. Subject to the terms of this Agreement, each Stockholder hereby irrevocably and unconditionally agrees that
it shall, during the time this Agreement is in effect, at any annual or special meeting of the stockholders of the Company, however called,
including any adjournment or postponement thereof, and in connection with any action proposed to be taken by written consent of the stockholders
of the Company, such Stockholder shall, in each case, to the fullest extent that such Stockholder’s Shares are entitled to vote
thereon: (i) if no Adverse Recommendation Change in connection with an Intervening Event has occurred and is continuing, such Stockholder
shall be present (in person or by proxy) and vote, or exercise its right to consent with respect to, all Shares held by such Stockholder
(A) in favor of the adoption of the Merger Agreement and the approval of the Offer and/or Merger, as applicable and (B) notwithstanding
Section 4.4, against any Takeover Proposal and any other proposal or action that would reasonably be expected to impede, interfere
with, delay or postpone the Merger Transactions or change in any manner the voting rights of any class of Shares; and (ii) if an
Adverse Recommendation Change has occurred and is continuing in connection with an Intervening Event, such Stockholder shall be present
(in person or by proxy) and vote, or exercise its right to consent with respect to, at least the Minimum Shares (A) in favor of the
adoption of the Merger Agreement and the approval of the Merger and (B) notwithstanding Section 4.4, against any Takeover
Proposal and any other proposal or action that would reasonably be expected to impede, interfere with, delay or postpone the Merger. Until
such Shares are accepted for purchase in the Offer, each Stockholder shall retain at all times the right to vote the Shares in such Stockholder’s
sole discretion, and without any other limitation, on any matters other than those set forth in this Section 1.2 that are
at any time or from time to time presented for consideration to the Company’s stockholders generally.

 

SECTION 2

 

REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDERS

 

Each Stockholder represents and warrants to Parent
and Merger Sub, severally but not jointly, that:

 

2.1
Organization; Authorization; Binding Agreement. If such Stockholder is an entity, such Stockholder is duly organized or formed,
as applicable, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated or constituted (to
the extent such concepts are recognized in such jurisdiction) and the consummation of the transactions contemplated hereby are within
such Stockholder’s corporate or organizational powers and have been duly authorized by all necessary corporate or organizational
actions on the part of such Stockholder. Such Stockholder has full power and authority, and if such Stockholder is an individual, also
has capacity, to execute, deliver and perform this Agreement and to consummate the transactions contemplated hereby. This Agreement has
been duly and validly executed and delivered by such Stockholder, and, assuming the due authorization, execution and delivery by each
of Parent and Merger Sub, constitutes a legal, valid and binding obligation of such Stockholder enforceable against such Stockholder in
accordance with its terms (subject to Enforceability Exceptions).

 

    2 

     

    

 

2.2
Non-Contravention. The execution and delivery of this Agreement by such Stockholder does not, and the performance by such Stockholder
of such Stockholder’s obligations hereunder and the consummation by such Stockholder of the transactions contemplated hereby will
not, (i) violate, any Law applicable to such Stockholder or such Stockholder’s Shares, (ii) except as may be required
by applicable federal securities laws, require any consent, approval, order, authorization, permit or other action by, or filing with
or notice to, any Person (including any Governmental Authority) under, constitute a default (with or without the giving of notice or the
lapse of time or both) under, or give rise to any right of termination, cancellation, modification or acceleration under, or result in
the creation of any Liens on any of the Shares pursuant to, any Contract, trust, Orders or other instrument binding on such Stockholder
or such Stockholder’s Shares or any applicable Law, or (iii) if such Stockholder is an entity, violate, contravene or conflict
with or result in any breach of any provision of such Stockholder’s organizational documents, in case of each of clauses (i), (ii) and
(iii), except as would not reasonably be expected to adversely affect the ability of such Stockholder to perform its obligations under
this Agreement in any material respect or to consummate the transactions contemplated hereby in a timely manner.

 

2.3
Ownership of Shares; Total Shares. Such Stockholder (together with such Stockholder’s spouse if such Stockholder is married
and the Shares constitute community property under applicable Laws) is the record or beneficial owner (as defined in Rule 13d-3 under
the Exchange Act) of the number of Shares set forth opposite such Stockholder’s name on Schedule A and owns such Shares free
and clear of any Liens, except as provided hereunder or pursuant to any applicable restrictions on transfer under the Securities Act (collectively,
 “Permitted Share Liens”). Except as set forth on Schedule A, such Stockholder does not have any interest in or voting
rights with respect to any other securities of the Company. If such Stockholder is a party to the Stockholders Agreement referenced below,
such Stockholder, on behalf of itself and its Affiliates, hereby waives and releases, and agrees to refrain from exercising, any right
to terminate the Stockholders Agreement, and any other rights thereunder that are inconsistent with this Agreement, the Offer, the Merger,
or any of the transactions contemplated hereby or thereby.

 

2.4
Voting Power. Other than as provided in this Agreement, such Stockholder has full voting power with respect to all such Stockholder’s
Shares, and full power of disposition, full power to issue instructions with respect to the matters set forth herein and full power to
agree to all of the matters set forth in this Agreement, in each case with respect to all of such Stockholder’s Shares. None of
such Stockholder’s Shares are subject to any stockholders’ agreement, proxy, voting trust or other agreement or arrangement
with respect to the voting of such Shares, except for the agreement referenced on Schedule A (the “Stockholders Agreement”).
The Stockholders Agreement remains in full force and effect and no Stockholder has given or received notice that it shall be terminated.

 

2.5
Reliance. Such Stockholder understands and acknowledges that Parent and Merger Sub are entering into the Merger Agreement in
reliance upon such Stockholder’s execution, delivery and performance of this Agreement.

 

2.6
Absence of Litigation. There is no Legal Action or Order pending against, or, to the knowledge of such Stockholder, threatened
in writing against such Stockholder or any of such Stockholder’s properties or assets (including the Shares) that would reasonably
be expected to prevent or materially delay or impair the consummation by such Stockholder of the transactions contemplated by this Agreement
or otherwise adversely impact such Stockholder’s ability to perform its obligations hereunder in any material respect.

 

2.7
Brokers. No broker, finder, financial advisor, investment banker or other Person is entitled to any brokerage, finder’s,
financial advisor’s or other similar fee or commission from the Company in connection with such Stockholder tendering its Shares
pursuant to this Agreement based upon arrangements made by, or to the knowledge of such Stockholder, on behalf of such Stockholder in
its capacity as such.

 

SECTION 3

 

REPRESENTATIONS AND WARRANTIES OF PARENT AND
MERGER SUB

 

Each of Parent and Merger Sub represent and warrant
to each of the Stockholders, jointly and severally, that:

 

3.1
Organization; Authorization. Each of Parent and Merger Sub is duly organized or formed, as applicable, validly existing and
in good standing under the laws of the jurisdiction in which it is organized (in the case of good standing, to the extent the concept
is recognized by such jurisdiction). The consummation of the transactions contemplated hereby are within each of Parent’s and Merger
Sub’s corporate powers and have been duly authorized by all necessary corporate actions on the part of Parent and Merger Sub. Each
of Parent and Merger Sub has all requisite corporate power and authority to execute and deliver this Agreement and to consummate the transactions
contemplated thereby.

 

    3 

     

    

 

3.2
Binding Agreement. Each of Parent and Merger Sub has duly executed and delivered this Agreement, and, assuming the due authorization,
execution and delivery by each Stockholder, this Agreement constitutes its legal, valid and binding obligation of Parent and Merger Sub,
enforceable against Parent and Merger Sub in accordance with its terms (subject to the Enforceability Exceptions).

 

SECTION 4

 

ADDITIONAL COVENANTS OF THE STOCKHOLDERS

 

Each Stockholder hereby covenants and agrees,
severally but not jointly, that until the termination of this Agreement:

 

4.1
No Transfer; No Inconsistent Arrangements.

 

(a) From and after the date hereof and until
this Agreement is terminated in accordance with Section 5.2, subject to Section 4.1(b), such Stockholder shall
not, directly or indirectly, (i) create or permit to exist any Liens, other than Permitted Share Liens, on any or all of such Stockholder’s
Shares, (ii) transfer, sell, assign, gift, hedge, pledge or otherwise dispose (whether by sale, liquidation, dissolution, dividend,
distribution or otherwise) of, or enter into any derivative arrangement with respect to (collectively, “Transfer”),
any of such Stockholder’s Shares, or any right or interest therein (or consent to any of the foregoing), (iii) enter into any
Contract with respect to any Transfer of such Stockholder’s Shares or any interest therein, (iv) grant or permit the grant
of any proxy, power-of-attorney or other authorization or consent in or with respect to any of such Stockholder’s Shares, (v) deposit
or permit the deposit of any of such Stockholder’s Shares into a voting trust or enter into a voting agreement or arrangement with
respect to any of such Stockholder’s Shares, or (vi) take or permit any other action that would reasonably be expected to in
any way restrict, limit, interfere with or delay the performance of such Stockholder’s obligations hereunder or the transactions
contemplated hereby or otherwise make any representation or warranty of such Stockholder herein untrue or incorrect in any material respect.
Any action taken in violation of the foregoing sentence shall be null and void ab initio and such Stockholder agrees that any such
prohibited action may and should be enjoined. If any involuntary Transfer of any or all of such Stockholder’s Shares shall occur
(including, if applicable, a sale by such Stockholder’s trustee in any bankruptcy, or a sale to a purchaser at any creditor’s
or court sale), the transferee (which term, as used herein, shall include any and all transferees and subsequent transferees of the initial
transferee) shall take and hold such Shares, subject to all of the restrictions, liabilities and rights under this Agreement, which shall
continue in full force and effect until valid termination of this Agreement. Such Stockholder agrees that it shall not, and shall cause
each of its controlled Affiliates not to, and shall not encourage, direct or instruct each of its non-controlled Affiliates to, become
a member of a “group” (as defined under Section 13(d) of the Exchange Act) with respect to any Company securities
for the purpose of opposing or competing with or taking any actions inconsistent with the transactions contemplated by the Merger Agreement.

 

(b) Notwithstanding the foregoing Section 4.1(a),
such Stockholder may make Transfers of Shares (x) to any “Permitted Transferee” (as defined below), in which case the
Shares shall continue to be bound by this Agreement and provided that any such Permitted Transferee agrees in writing to be bound by the
terms and conditions of this Agreement with respect to such Shares that are subject to such Transfer prior to (or, in the case of a Stockholder’s
death or other involuntary transfer, as soon as practicable after) the consummation of any such Transfer, or (y) as Parent may otherwise
agree in writing in its reasonable discretion. A “Permitted Transferee” means, with respect to any Stockholder, (I) a
spouse, lineal descendant or antecedent, brother or sister, adopted child or grandchild, or the spouse of any child, adopted child, grandchild,
or adopted grandchild of such Stockholder, (II) any charitable organization described in Section 170(c) of the Code, (III) any
trust, the beneficiaries of which include only the Persons named in clause (I) or (II) of this definition, (IV) any corporation,
limited liability company, or partnership, the stockholders, members, and general or limited partners of which include only the Persons
named in clause (I) or (II) of this definition, or (V) in the case of a Stockholder’s death, the estate of such Stockholder
or the executor, administrator, or other representative of such estate.

 

4.2
No Exercise of Appraisal Rights; Actions. Such Stockholder (i) waives and agrees not to exercise any appraisal rights
in respect of such Stockholder’s Shares that may arise with respect to the Merger and (ii) agrees not to commence or take any
action to join in any class action with respect to, any claim, derivative or otherwise, against Parent, Merger Sub, the Company or any
of their respective successors (A) challenging the validity of, or seeking to enjoin the operation of, any provision of this Agreement
or (B) alleging breach of any fiduciary duty of any Person in connection with the negotiation and entry into the Merger Agreement
or the consummation of the Merger Transactions, including, without limitation, the Merger.

 

    4 

     

    

 

4.3
Documentation and Information. Except as required by applicable Laws (including without limitation, the filing of a Schedule
13D with the SEC which may include this Agreement as an exhibit thereto), such Stockholder shall not make any public announcement regarding
this Agreement, the Merger Agreement, the Merger Transactions or the transactions contemplated hereby without the prior written consent
of Parent (such consent not to be unreasonably withheld, conditioned or delayed). Such Stockholder consents to and hereby authorizes Parent
and Merger Sub to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document
that Parent or Merger Sub reasonably determines to be necessary in connection with the Offer, the Merger and any transactions contemplated
by the Merger Agreement, such Stockholder’s identity and ownership of the Shares, the existence of this Agreement and the nature
of such Stockholder’s commitments and obligations under this Agreement, and such Stockholder acknowledges that Parent and Merger
Sub may, in Parent’s sole discretion, file this Agreement or a form hereof with the SEC or any other Governmental Authority. Such
Stockholder agrees to promptly give Parent any information it may reasonably require for the preparation of any such disclosure documents,
and such Stockholder agrees to promptly notify Parent of any required corrections with respect to any written information supplied by
it specifically for use in any such disclosure document, if and to the extent that such Stockholder shall become aware that any such information
shall have become false or misleading in any material respect.

 

4.4
No Solicitation. Subject to Section 5.15, each Stockholder shall not, and, if not an individual, shall cause its
controlled Affiliates not to, and shall direct its other Representatives not to, and shall not direct, encourage or instruct its Affiliates
to, directly or indirectly, (i) initiate or continue any solicitation, knowing encouragement, knowing facilitation, discussions or
negotiations with any Persons with respect to a Takeover Proposal or (ii) solicit, initiate or knowingly facilitate or knowingly
encourage (including by way of furnishing non-public information) any inquiries regarding, or the making of any proposal or offer that
constitutes, or could reasonably be expected to lead to, a Takeover Proposal, (iii) engage in, continue or otherwise participate
in any activities, discussions or negotiations regarding, or furnish to any other Person any information in connection with or for the
purpose of knowingly encouraging or facilitating, a Takeover Proposal or any proposal or offer that could reasonably be expected to lead
to a Takeover Proposal, or (iv) endorse, approve or enter into any letter of intent, acquisition agreement, agreement in principle
or similar agreement with respect to a Takeover Proposal or any proposal or offer that could reasonably be expected to lead to a Takeover
Proposal or to prevent such Stockholder from complying with its obligations under this Section 4.4, or requiring or that would reasonably
be expect to cause the Company to abandon, terminate, delay or fail to consummate, or that would otherwise reasonably impede, interfere
with or be inconsistent with, the Offer or the Merger. Notwithstanding anything to the contrary provided in this Agreement, each Stockholder
and its Affiliates and Representatives shall not be prohibited from participating in any discussions or negotiations with respect to a
possible tender and support, voting or similar agreement in connection with a Takeover Proposal in the event that the Company is permitted
to take the actions set forth in Section 5.4(b) or Section 5.4(e) of the Merger Agreement with respect
to such Takeover Proposal.

 

4.5
Adjustments. In the event of any stock split, stock dividend, reverse stock split, consolidation of shares, merger, reorganization,
recapitalization, reclassification, combination, exchange of shares or similar transaction with respect to the capital stock of the Company
that affects the Shares, the terms of this Agreement shall apply to the resulting securities as well as such stock dividends and distributions.

 

4.6
Notice of Acquisitions; Proposals Regarding Prohibited Transactions. Each Stockholder hereby agrees to promptly notify Parent
(i) of the number of any additional Shares or other securities of the Company of which such Stockholder acquires record or beneficial
ownership on or after the date hereof, and (ii) if the Stockholder receives any Takeover Proposal or any inquiries that would reasonably
be expected to lead to a Takeover Proposal, then such stockholder will promptly inform the Company Board of the Takeover Proposal or inquiry
so that the Company may fulfill its obligations under Section 5.4 of the Merger Agreement, and such Stockholder shall identify
to the Company Board the Person making such Takeover Proposal or inquiry and specify the material terms and conditions of such Takeover
Proposal or such inquiry (including any copies of each Takeover Proposal and any subsequent amendments or modifications thereto that are
available to such stockholder).

 

    5 

     

    

 

SECTION 5

 

MISCELLANEOUS

 

5.1
Notices. Any notice or other communication required or permitted to be delivered to any party under this Agreement shall be
in writing and shall be deemed to have been delivered and received (i) if delivered in person, on the day of such delivery, (ii) if
by email, on the day on which such email was sent; provided, that receipt is confirmed, (iii) if by certified or registered mail
(return receipt requested), on the fifth Business Day after the mailing thereof or (iv) if by reputable overnight delivery service,
on the second Business Day after the sending thereof; provided, that in each case, the notice or other communication is sent to
the respective parties at the following addresses (or at such other address for a party as shall be specified by like notice): (A) if
to Parent or Merger Sub, in accordance with the provisions of the Merger Agreement and (B) if to a Stockholder, to such Stockholder’s
address or email address set forth on a signature page hereto, or to such other address or email address as such party may hereafter
specify in writing for the purpose by notice to each other party hereto.

 

5.2
Termination. This Agreement shall terminate automatically, without any notice or other action by any Person, upon the first
to occur of (i) the valid termination of the Merger Agreement in accordance with its terms, (ii) the Effective Time, (iii) the
date of any material modification, waiver or amendment to any provision of the Merger Agreement that reduces the amount or changes the
form of the consideration payable to the Stockholder pursuant to the Merger Agreement as in effect on the date hereof or (iv) the
mutual written consent of each of Parent, Merger Sub and the Stockholders holding a majority in interest of the voting power of all Stockholders
(“Required Stockholder Consent”). Upon termination of this Agreement, no party shall have any further obligations or
liabilities under this Agreement; provided, that (A) nothing set forth in this Section 5.2 shall relieve any party
from liability for any willful and material breach of this Agreement prior to termination hereof and (B) the provisions of this Section 5
shall survive any termination of this Agreement.

 

5.3
Amendment. This Agreement may not be amended except by an instrument in writing signed on behalf of Parent, Merger Sub and
Stockholders constituting the Required Stockholder Consent; provided that this Agreement may not be amended or modified with respect
to any Stockholder without the written consent of such Stockholder if such amendment or modification would reasonably be expected to adversely
affect the rights and obligations of such Stockholder hereunder.

 

5.4
Waiver. No failure on the part of any party to exercise any power, right, privilege or remedy under this Agreement, and no
delay on the part of any party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of
such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude
any other or further exercise thereof or of any other power, right, privilege or remedy. No party shall be deemed to have waived any claim
arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power,
right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such party which, for
purposes of the Stockholders, shall be the Required Stockholder Consent; and any such waiver shall not be applicable or have any effect
except in the specific instance in which it is given. Notwithstanding the foregoing, no provision hereof shall be waived with respect
to any Stockholder without the written consent of such Stockholder if such waiver would reasonably be expected to materially and adversely
affect the rights and obligations of such Stockholder hereunder.

 

5.5
Expenses. All fees and expenses incurred in connection herewith and the transactions contemplated hereby shall be paid by the
party incurring such expenses, whether or not the Offer or the Merger is consummated.

 

5.6
Assignment. This Agreement shall be binding upon and shall be enforceable by and inure solely to the benefit of, the parties
hereto and their respective successors and permitted assigns. Neither this Agreement nor any of the rights or obligations hereunder may
be assigned by any Stockholder without the prior written consent of Parent, except to the extent that such rights are assigned pursuant
to a Transfer expressly permitted under Section 4.1, and any attempted assignment of this Agreement or any of such rights
without such consent shall be void and of no effect. No assignment by any party shall relieve such party of any of its obligations hereunder.

 

5.7
No Third Party Beneficiaries. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person
(other than the parties hereto) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

 

    6 

     

    

 

5.8
Applicable Laws; Jurisdiction; Specific Performance; Remedies.

 

(a) This Agreement shall be governed by,
and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable
principles of conflicts of laws thereof. Subject to Section 5.8(c), in any action or proceeding arising out of or relating
to this Agreement or any of the transactions contemplated by this Agreement: (A) each of the parties irrevocably and unconditionally
consents and submits to the exclusive jurisdiction and venue of the Chosen Courts (it being agreed that the consents to jurisdiction and
venue set forth in this Section 5.8 shall not constitute general consents to service of process in the State of Delaware and
shall have no effect for any purpose except as provided in this paragraph and shall not be deemed to confer rights on any Person other
than the parties hereto); (B) agrees that it will not attempt to deny or defeat such personal jurisdiction by motion or other request
for leave from any such Chosen Court; (C) agrees that any actions or proceedings arising in connection with this Agreement or the
transactions contemplated hereby shall be brought, tried and determined only in the Chosen Courts; (D) waives any claim of improper
venue or any claim that the Chosen Courts are an inconvenient forum; (E) agrees that it will not bring any action relating to this
Agreement or the transactions contemplated hereby in any court other than the Chosen Courts; and (F) each of the parties irrevocably
consents to service of process by first class certified mail, return receipt requested, postage prepaid, to the address at which such
party is to receive notice in accordance with Section 5.1 (Notices). The parties hereto agree that a final judgment in any
such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner
provided by applicable Laws; provided, that nothing in the foregoing shall restrict any party’s rights to seek any post-judgment
relief regarding, or any appeal from, such final trial court judgment.

 

(b) The parties agree that irreparable damage
for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that the parties hereto do not
perform their obligations under the provisions of this Agreement in accordance with its specified terms or otherwise breach such provisions.
Subject to the following sentence, the parties acknowledge and agree that the parties shall be entitled to seek an injunction or injunctions,
specific performance, or other equitable relief, to prevent breaches of this Agreement and to enforce specifically the terms and provisions
hereof in the courts described in Section 5.8(a) without proof of damages or otherwise, this being in addition to any
other remedy to which they are entitled under this Agreement. The parties will waive the defense of adequacy of a remedy at law and the
parties hereto acknowledge and agree that any party seeking an injunction or injunctions to prevent breaches of this Agreement and to
enforce specifically the terms and provisions of this Agreement in accordance with this Section 5.8(b) shall not be required
to provide any bond or other security in connection with any such order or injunction.

 

(c) EACH PARTY ACKNOWLEDGES AND AGREES THAT
ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH
PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION DIRECTLY OR
INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER DOCUMENTS AND AGREEMENTS DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS
CONTEMPLATED HEREBY OR THEREBY. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE OF ANY OTHER PARTY
HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL
ACTION, (II) SUCH PARTY HAS CONSIDERED AND UNDERSTANDS THE IMPLICATIONS OF THIS WAIVER, (III) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY
AND (IV) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN
THIS SECTION 5.8(c).

 

5.9
Entire Agreement; Counterparts. This Agreement and the schedules referred to herein, together with the Merger Agreement, constitute
the entire agreement and supersedes all prior agreements and understandings, both written and oral, among or between the parties, with
respect to the subject matter hereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original
and all of which shall constitute one and the same instrument. Facsimile and electronic signatures, or signatures received as a .pdf attachment
to electronic mail, shall be treated as original signatures for all purposes of this Agreement. The exchange of a fully executed Agreement
(in counterparts or otherwise) by .pdf shall be sufficient to bind the parties to the terms and conditions of this Agreement.

 

5.10
Severability. The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision
shall not affect the validity or enforceability of the other provisions of this Agreement. If any provision of this Agreement, or the
application of that provision to any Person or any circumstance, is determined by a court of competent jurisdiction to be invalid or unenforceable,
then (i) the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties
as closely as possible to the fullest extent permitted by applicable Law and (ii) the remainder of this Agreement and the application
of that provision to other Persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity
or unenforceability affect the validity or enforceability of that provision, or the application of that provision, in any other jurisdiction.

 

    7 

     

    

 

5.11
Headings. The bold-faced headings contained in this Agreement are for convenience of reference only, shall not be deemed to
be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.

 

5.12
Mutual Drafting. The parties have participated jointly in negotiating and drafting this Agreement. If an ambiguity or a question
of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden
of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.

 

5.13
Further Assurances. Parent, Merger Sub and each Stockholder will execute and deliver, or cause to be executed and delivered,
all further documents and instruments and use their respective reasonable best efforts to take, or cause to be taken, all actions and
to do, or cause to be done, all things necessary, proper or advisable under applicable Laws, to perform their respective obligations under
this Agreement.

 

5.14
Interpretation. Unless the context otherwise requires, as used in this Agreement: (i) “or” is not exclusive;
(ii) “including” and its variants mean “including, without limitation” and its variants; (iii) words
defined in the singular have the parallel meaning in the plural and vice versa; (iv) words of one gender shall be construed to apply
to each gender; (v) the terms “Section” and “Schedule” refer to the specified Section or Schedule of
or to this Agreement; and (vi) the words “hereof,” “herein” and “hereunder” and words of similar
import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement.

 

5.15
Capacity as Stockholder. Notwithstanding anything herein to the contrary, (i) each Stockholder signs this Agreement solely
in such Stockholder’s capacity as a stockholder of the Company, and not in any other capacity, and this Agreement shall not limit
or otherwise affect the actions of such Stockholder or any affiliate, employee or designee of such Stockholder or any of its affiliates
in its capacity, if applicable, as an officer or director of the Company, and (ii) nothing herein shall in any way restrict a director
or officer of the Company in the taking of any actions (or failure to act) in his or her capacity as a director or officer of the Company,
or in the exercise of his or her fiduciary duties as a director or officer of the Company, or prevent or be construed to create any obligation
on the part of any director or officer of the Company from taking any action in his or her capacity as such director or officer.

 

5.16
No Agreement Until Executed. This Agreement shall not be effective unless and until (i) the Merger Agreement is executed
by all parties thereto, and (ii) this Agreement is executed by all parties hereto.

 

5.17
No Ownership Interest. Except as otherwise provided herein, nothing contained in this Agreement shall be deemed to vest in
Parent or Merger Sub any direct or indirect ownership or incidence of ownership of or with respect to the Shares. All rights, ownership
and economic benefits of and relating to the Shares shall remain vested in and belong to each applicable Stockholder, and neither Parent
nor Merger Sub shall have any authority to manage, direct, restrict, regulate, govern, or administer any of the policies or operations
of the Company or exercise any power or authority to direct such Stockholder in the voting of any of the Shares, except as otherwise provided
herein.

 

5.18
Stockholder Obligations Several and Not Joint. The obligations of each Stockholder hereunder shall be several and not joint,
and no Stockholder shall be liable for any breach of the terms of this Agreement by any other Stockholder.

 

[Signature Pages Follow]

 

    8 

     

    

 

 

The parties are executing this Agreement on the date first set forth
above.

 

		 	SPEEDWAY MOTORSPORTS, LLC

 

		 	By:	/s/ Marcus G. Smith

		 	Name:	Marcus G. Smith

	 	 	Title:	Chief Executive Officer and President

 

	 	 	SPEEDCO II, INC.

 

	 	 	By:	/s/ Marcus G. Smith

	 	 	Name:	Marcus G. Smith

	 	 	Title:	Chief Executive Officer and President

 

[SIGNATURE
PAGE TO THE TENDER AND
SUPPORT AGREEMENT – PARENT
AND MERGER SUB]

 

     

     

    

 

The parties are executing this Agreement on the date first set forth
above.

 

	 	 	HENRY B. TIPPIE

 

	 	 	By:	/s/ Henry B. Tippie

	 	 	Email:	[*]

	 	 	Address:	[*]

 

[SIGNATURE
PAGE TO THE TENDER AND
SUPPORT AGREEMENT – HENRY
B. TIPPIE]

 

     

     

    

 

The parties are executing this Agreement on the date first set forth
above.

 

	 	 	Jeffrey W. Rollins

 

	 	 	By:	/s/ Jeffrey W. Rollins

	 	 	Email:	[*]

	 	 	Address:	[*]

 

[SIGNATURE
PAGE TO THE TENDER AND
SUPPORT AGREEMENT – JEFFREY
W. ROLLINS]

 

     

     

    

 

 

The parties are executing this Agreement on the date first set forth
above.

 

	 	 	Gary W. Rollins

 

	 	 	By:	/s/ Gary W. Rollins

	 	 	Email:	[*]

	 	 	Address:	[*]

 

[SIGNATURE
PAGE TO THE TENDER AND
SUPPORT AGREEMENT – GARY
W. ROLLINS]

 

     

     

    

 

The parties are executing this Agreement on the date first set forth
above.

 

	 	 	THE RMT TRUST

 

	 	 	By:	/s/ Henry B. Tippie

	 	 	Name:	Henry B. Tippie

	 	 	Its:	Trustee

	 	 	Email:	[*]

	 	 	Address:	[*]

 

[SIGNATURE
PAGE TO THE TENDER AND
SUPPORT AGREEMENT – THE
RMT TRUST] 

 

     

     

    

 

The parties are executing this Agreement on the date first set forth
above.

 

	 	 	MICHAEL TATOIAN

 

	 	 	By:	/s/ Michael Tatoian

	 	 	Email:	[*]

	 	 	Address:	[*]

 

[SIGNATURE
PAGE TO THE TENDER AND
SUPPORT AGREEMENT – MICHAEL
TATOIAN]

 

     

     

    

 

The parties are executing this Agreement on the date first set forth
above.

 

	 	 	Timothy Horne

 

	 	 	By:	/s/ Timothy R. Horne

	 	 	Email:	[*]

	 	 	Address:	[*]

 

[SIGNATURE
PAGE TO THE TENDER AND
SUPPORT AGREEMENT – TIMOTHY
HORNE]

 

     

     

    

 

The parties are executing this Agreement on the date first set forth
above.

 

	 	 	Thomas winterMantel

 

	 	 	By:	/s/ Thomas Wintermantel

	 	 	Email:	[*]

	 	 	Address:	[*]

 

[SIGNATURE
PAGE TO THE TENDER AND
SUPPORT AGREEMENT – THOMAS
WINTERMANTEL]

 

     

     

    

 

The parties are executing this Agreement on the date first set forth
above.

 

	 	 	Denis McGlynn

 

	 	 	By:	/s/ Denis McGlynn

	 	 	Email:	[*]

	 	 	Address:	[*]

 

[SIGNATURE
PAGE TO THE TENDER AND
SUPPORT AGREEMENT – DENIS
MCGLYNN]

 

     

     

    

 

The parties are executing this Agreement on the date first set forth
above.

 

	 	 	Louise McGlynn

 

	 	 	By:	/s/ Louise McGlynn

	 	 	Email:	[*]

	 	 	Address:	[*]

 

[SIGNATURE
PAGE TO THE TENDER AND
SUPPORT AGREEMENT – LOUISE
MCGLYNN]

 

     

     

    

 

The parties are executing this Agreement on the date first set forth
above.

 

	 	 	Patrick Bagley

 

	 	 	By:	/s/ Patrick Bagley

	 	 	Email:	[*]

	 	 	Address:	[*]

 

[SIGNATURE
PAGE TO THE TENDER AND
SUPPORT AGREEMENT – PATRICK
BAGLEY]

 

     

     

    

 

The parties are executing this Agreement on the date first set forth
above.

 

	 	 	Radcliffe Hastings

 

	 	 	By:	/s/ Radcliffe Hastings

	 	 	Email:	[*]

	 	 	Address:	[*]

 

[SIGNATURE
PAGE TO THE TENDER AND
SUPPORT AGREEMENT – RADCLIFFE
HASTINGS]

 

     

     

    

 

The parties are executing this Agreement on the date first set forth
above.

 

	 	 	Nevada Oversight, Inc., not personally,
    but as trustee of The Marital Trust held under R. Randall Rollins 2012 Trust

 

	 	 	By:	/s/ Donald Carson

	 	 	Name:	Donald Carson

	 	 	Its:	President

	 	 	Email:	[*]

	 	 	Address:	[*]

 

[SIGNATURE
PAGE TO THE TENDER AND
SUPPORT AGREEMENT – NEVADA
OVERSIGHT, INC., NOT PERSONALLY, BUT AS TRUSTEE
OF THE MARITAL TRUST HELD
UNDER R. RANDALL ROLLINS
2012 TRUST]

 

     

     

    

 

Schedule A

 

	Stockholder	 	Shares	 	 	Common
 Stock	 	 	Class A
 Stock	 	 	Minimum Shares	 	 	Minimum Common

Stock	 	 	Minimum
 Class A 
 Stock	 
	Henry B. Tippie	 	 	4,500,000	 	 	 	1,000,000	 	 	 	3,500,000	 	 	 	2,002,500	 	 	 	445,000	 	 	 	1,557,500	 
	Jeffrey W. Rollins	 	 	1,181,265	 	 	 	27,290	 	 	 	1,153,975	 	 	 	525,663	 	 	 	12,144	 	 	 	513,519	 
	Gary W. Rollins	 	 	2,794,200	 	 	 	290,700	 	 	 	2,503,500	 	 	 	1,243,419	 	 	 	129,362	 	 	 	1,114,058	 
	The RMT Trust	 	 	8,000,000	 	 	 	0	 	 	 	8,000,000	 	 	 	3,560,000	 	 	 	0	 	 	 	3,560,000	 
	Mike Tatoian	 	 	183,168	 	 	 	183,168	 	 	 	0	 	 	 	81,510	 	 	 	81,510	 	 	 	0	 
	Tim Horne	 	 	202,497	 	 	 	202,497	 	 	 	0	 	 	 	90,111	 	 	 	90,111	 	 	 	0	 
	Tom Wintermantel	 	 	145,077	 	 	 	145,077	 	 	 	0	 	 	 	64,559	 	 	 	64,559	 	 	 	0	 
	Denis McGlynn	 	 	869,395	 	 	 	338,867	 	 	 	530,528	 	 	 	386,881	 	 	 	150,796	 	 	 	236,085	 
	Louise McGlynn	 	 	252,000	 	 	 	20,000	 	 	 	232,000	 	 	 	112,140	 	 	 	8,900	 	 	 	103,240	 
	Patrick Bagley	 	 	24,271	 	 	 	24,271	 	 	 	0	 	 	 	10,801	 	 	 	10,801	 	 	 	0	 
	Radcliffe Hastings	 	 	4,146	 	 	 	4,146	 	 	 	0	 	 	 	1,845	 	 	 	1,845	 	 	 	0	 
	Nevada Oversight, Inc,. not personally, but as Trustee of the Marital Trust Held Under R. Randall Rollins 2012 Trust	 	 	2,794,200	 	 	 	290,700	 	 	 	2,503,500	 	 	 	1,243,419	 	 	 	129,362	 	 	 	1,114,058	 
	Total	 	 	20,950,219	 	 	 	2,526,716	 	 	 	18,423,503	 	 	 	9,322,847	 	 	 	1,124,389	 	 	 	8,198,459	 

 

The Shares listed above owned by Henry B. Tippie, Jeffrey W. Rollins,
and the RMT Trust are subject to that certain Stockholders Voting Agreement and Irrevocable Proxy dated as of January 31, 2008 by
and among Henry B. Tippie, R. Randall Rollins and Michele M. Rollins, as amended.Exhibit 10.16

 

DEVELOPMENT,
COLLABORATION AND

 

LICENSE
AGREEMENT

 

Dated
September 13th, 2016

 

by
and between

 

JUPITER
ORPHAN THERAPEUTICS, INC,

a corporation incorporated under the laws of Delaware , having its principal place of business at

601 Heritage Drive Suite#137, Jupiter, Florida, 33458 USA

 

and

 

AQUANOVA
AG,

a corporation incorporated under the laws of Germany, having its principal place of business at

Birkenweg 8-10, 64295 Darmstadt, Germany

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 1 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

DEVELOPMENT,
COLLABORATION AND LICENSE AGREEMENT

 

This
Development, Collaboration and License Agreement (“Agreement”), dated September 13th, 2016 (the “Effective
Date”) is made by and between Jupiter Orphan Therapeutics, Inc. (“JOT”), a corporation organized under the
laws of Delaware, United States of America and Aquanova AG a company organized under the laws of Germany (“Aquanova”)
(each a “Party” and collectively, the “Parties”).

 

P
R E A M B L E

 

Aquanova
is a well-established German company in the field of development, manufacturing and selling of colloidal formulas with 20 years of experience.
The company has developed a proprietary solubilization and micelle delivery technology for the formulation of raw materials and active
ingredients for but not limited to the food, beverage, dietary supplement, cosmetics and pharmaceutical segments.

 

JOT
is a US-based pharmaceutical company with experience in the research, development, manufacturing and commercialization of pharmaceutical
products.

 

Orphan
diseases represent a very large market worldwide for suitable pharmaceutical products;

 

JOT
is committed to bring to the market pharmaceutical products for primarily orphan diseases in the U.S. and worldwide;

 

JOT
is aware and accepts that Aquanova sells formulations worldwide primarily to manufactures in the food, beverage, dietary supplements
and other segments, which is not meant and must not be restricted by this Agreement in any way except in areas that is effected by the
content of this agreement;

 

Aquanova
is aware and accepts that JOT has to use, by competitive nature and/or for regulatory reason, the best possible product for each specific
treatment JOT will approach a solution for. This might mean that the Aquanova technology referred to in this agreement will not be used
for certain disease areas;

 

The
intent of the collaboration between the Parties is meant to create a differentiated and well defined new product offer in the pharmaceutical
segment;

 

Both
parties are interested in creating a pharmaceutic product with the focus on the treatment of orphan diseases with ingredients already
in use for non-pharmaceutic products and are willing to engage in a collaboration to create a product that gets approved by the respective
responsible regulatory bodies as a pharmaceutical product. The parties expect a timeline from beginning of their collaboration until
product launch of roughly 24 to 48 months.

 

Aquanova
and JOT desire that Aquanova develops (a) Formulation(s) for the active Ingredient(s) as specified in Appendix 1 for development and
commercialization of Products by JOT in the Territory, subject to the terms and conditions of this Agreement;

 

NOW,
THEREFORE, in consideration of the mutual covenants set forth in this Agreement, JOT and Aquanova hereby agree as follows:

 

Article
I.

DEFINITIONS

 

Unless
specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective
meanings set forth below:

 

“Active
Ingredient (“API”)” means the clinically active material as specified in Appendix 1 for use in a pharmaceutical
Product. Bachem is the supplier of the API used to date but other qualified sources of an equivalent  material may be utilized to
achieve the final product. This Appendix will be updated as alternative active materials and/or suppliers will be involved.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 2 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

“Affiliate”
means a legal entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common
control with a Party. For purposes of this definition only, “control” and, with correlative meanings, the terms “controlled
by” and “under common control with” means (a) the possession, directly or indirectly, of the power to direct the management
or policies of a legal entity, whether through the ownership of voting securities or by contract relating to voting rights or corporate
governance, or (b) the ownership, directly or indirectly, of more than 50% of the voting securities or other ownership interest of a
legal entity; provided, however, that if local law restricts foreign ownership, control shall be established by direct or indirect
ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests.

 

“Applicable
Law” means the applicable laws, rules, regulations, guidelines or other requirements of any Governmental Authority.

 

“Aquanova
Know-How” means all know-how relating to the Solubilization and Micelle Technology or a Product that is (a) Controlled by Aquanova
or any of its Affiliates at any time, and (b) necessary or useful for the Development, Manufacture, use or Commercialization of a Product.

 

“Business
Day” means a day other than (a) a Saturday or a Sunday, (b) a bank or other public holiday in Darmstadt, Germany, or (c) a
bank or other public holiday in Jupiter, Florida, U.S.

 

“Clinical
Trial” means any human clinical trial of a Product.

 

“Co-Packaged
Combination Product” or “CCP” means a product comprised of one or more Products and one or more separate pharmaceutical
products (that do not constitute a Product), kits, tests, items of equipment or other components that are either packaged together or
sold together for a single price as a co-packaged product.

 

“Combination
Product” means either a Co-Packaged Combination Product or a Fixed-Dose Combination Product. All references to a Product in
this Agreement shall be deemed to include a Combination Product.

 

“Commercialization
Activities” means commercialization activities relating to a Product, including activities relating to marketing, promoting,
detailing, distributing, importing, exporting, offering for sale and/or selling a Product, the conduct of other commercialization activities
(including activities in preparation for the commercial launch of a Product) and/or the conduct of any Phase IV clinical trials (as such
term is defined in 21 C.F.R. §312.85 and any foreign equivalent thereof). “Commercialize” and “Commercializing”
shall have their correlative meanings.

 

“Commercially
Reasonable Efforts” means, with respect to activities that a Party is required to perform hereunder for a Product, the level
of effort that would generally be used by a similarly situated pharmaceutical company to conduct such activities (taking into account
the minimum level of expenditure contemplated for such activities by the corresponding budget, if applicable) for any product owned by
it or to which it has exclusive rights, which product is of comparable market potential, profit potential or strategic value to such
Party and is at a similar stage in its development or product life, taking into account, without limitation, issues of safety and efficacy,
approved labelling, product profile, the patent and other proprietary position, the then current competitive environment for such product,
the likely timing of the product’s entry into the market, the then current market penetration, the return on investment potential
of such product, the regulatory environment and status of the product, and other relevant scientific, technical and commercial factors,
in each case as measured by the facts and circumstances at the time such efforts are due.

 

“Confidential
Information” means, with respect to a Party or any of its Affiliates, all Know-How and other proprietary information and data
of a financial, commercial or technical nature which the disclosing Party or any of its Affiliates has supplied or otherwise made available
to the other Party or its Affiliates, whether made available orally, in writing or in electronic form.

 

“Control”
means, when used in relation to an intellectual or other property right, the right of one Party to license or transfer such intellectual
or other property right to the other Party as provided in this Agreement without breaching any agreement or obligations to any other
Third Party.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 3 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

“Development
Activities” means any and all processes and activities conducted in researching, optimizing, and developing a Product and seeking,
obtaining and maintaining Regulatory Approvals for a Product, which may include research and development, formulation, preclinical testing,
toxicology, clinical studies, quality of life assessments, pharmacoeconomics, and regulatory affairs. “Development”
and “Develop” shall have their correlative meanings.

 

“EMA”
means the European Medicines Agency, or any successor regulatory agency.

 

“FDA”
means the U.S. Food and Drug Administration, or any successor regulatory agency.

 

“FDC
Act” means the U.S. Federal Food, Drug and Cosmetic Act, as amended.

 

“Field”
means the use of Products for humans and animals for the treatment of any of the Listed Indications, whether or not labeled for such
use.

 

“First
Commercial Sale” means the first sale for end use or consumption of a Product in any country following receipt of Regulatory
Approval in such country, but excluding Product distributed for free without payment or provision of any consideration such as promotional
samples.

 

“Fixed-Dose
Combination Product” means a pharmaceutical product that contains one or more JOT Compounds and one or more other Active Ingredients
(that do not constitute JOT Compounds).

 

“Formulation”
means any and all JOT customized recipes specifically created by Aquanova for the Active Ingredient as specified in Appendix 2 for
use, development and/or sales in the Product.

 

“Formulation
Development Activities” means any and all processes and activities conducted in researching, optimizing, and developing a Formulation
of the Active Ingredient to be used in the Product, which may include research and development, formulation, clinical and commercial
batch process development and optimization. “Formulation Development” shall have the correlative meaning.

 

“Good
Practices” means compliance with (a) the applicable standards contained in then-current “Good Laboratory Practices,”
“Good Manufacturing Practices” and/or “Good Clinical Practices,” as promulgated by the FDA and any foreign equivalents
thereof, and (b) all analogous guidelines and guidance documents promulgated by the International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human Use.

 

“Governmental
Authority” means any court, agency, department, authority or other instrumentality of any multi-national, national, state,
county, city, province or other political subdivision.

 

“IND”
means an Investigational New Drug Application (including any amendments thereto) filed with the FDA pursuant to 21 CFR Part 312 before
the commencement of a Clinical Trial of a Product, or any equivalent filing with any relevant Regulatory Authority in any jurisdiction.

 

“Initiate
the Approval Process” means (a) the filing for approval of a Product with the appropriate Regulatory Authority, (b) the initiation
of the clinical Development of a Product in the applicable country, or (iii) the initial filing with the appropriate Regulatory Authority
with respect to the clinical development plan for a Product.

 

“Joint
Patent Rights” means the listed patent (s) in Appendix 3 and its future updates, additions and national extensions.

 

“JOT
Compound” means an Active Ingredient to which JOT or any of its Affiliates Control JOT Know-How, Patent Rights and other intellectual
property rights sufficient to allow the Development, Manufacture and Commercialization in at least the Territory of a Product, including
any Active Ingredient that is being or has been Developed or Commercialized in a pharmaceutical product by or on behalf of JOT or any
of its Affiliates.

 

“JOT
Know-How” means all know-how relating to the JOT Compounds or the JOT Products that is (a) Controlled by JOT or any of its
Affiliates at any time, and (b) necessary or useful for the Development, Manufacture, use or Commercialization of a Product.

 

“JOT
Patent Rights” means all Patent Rights relating to the JOT Compounds or the JOT Products that (a) are Controlled by JOT or
any of its Affiliates at any time, and (b) claim the manufacture, use, composition of matter or formulation of a Product.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 4 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

“JOT
Products” means, with respect to a Product, all products identified on the applicable Product Schedule that contain the same
JOT Compound.

 

“Know-How”
means all information, materials and know-how, including any discoveries, improvements, experience, processes, formulae, data, inventions,
technology and trade secrets, solely restricted to enable a manufacturer having a FDA Approval to properly manufacture a Product.

 

“Listed
Indication(s)” means any pharmaceutical product with  the focus on, Orphan diseases, especially Friedreich’s Ataxia,
Lysosomal storage diseases, Tay-Sachs disease, Machado Joseph disease, Pancreatic Cancer and Alzheimer’s disease. Accordingly,
e.g. dietary supplements, cosmetics, food and beverages are not included. Any additional indications, that will be targeted at a later
date, will be added as amendments to this agreement.

 

“MAA”
means a New Drug Application, marketing authorization application, or other product registration application filed with any Regulatory
Authority to obtain approval to sell a Product in a country or jurisdiction, and all supplements, variations and other amendments thereof.

 

“Manufacture”
and “Manufacturing” means all activities related to the production, manufacture, processing, filling, finishing, packaging,
labeling, shipping, handling, holding, storage and warehousing of a Product or any intermediate thereof, including process development,
process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization,
stability testing, quality assurance and quality control.

 

“Market
Exclusivity Rights” means, on a country-by-country basis, unexpired rights provided by law or statute that provide a Product
with exclusive marketing rights in such country, including rights conferred as a result of: (a) a designation as a drug for rare diseases
or conditions under Sections 526 et seq. of the FDC Act, as amended (or the equivalent rights in any other country); (b) an exclusive
right to sell under a New Drug Application (“NDA”) pursuant to Section 505(b)(1) of the FDC Act, as amended (or the
equivalent rights in any other country); or (c) the completion of pediatric studies requested by the FDA under Section 505A(a) of the
FDC Act (or the equivalent rights in any other country).

 

“Named
Product” means any of the following: (a) a pharmaceutical product, whether or not containing a JOT Compound; (b) a new dosage
strength of an existing Product; (c) a Co-Packaged Combination Product; or (d) a Fixed-Dose Combination Product that, in each case, (i)
contains any of Resveratrol or any other Active ingredient according to Appendix 1,and (ii) is intended for the pharmaceutical use in
respect to the treatment of one of the Listed Indications.

 

“Net
Sales” means, with respect to any Product, the gross invoiced sales price of such Product sold by a Party or its Affiliates
(the “Selling Party”), in finished product form, packaged and labeled for sale, in arm’s length sales to Third
Parties, less deductions allowed to the Third Party customer by the Selling Party, to the extent actually taken by such Third Party customer,
on such sales for:

 

	 	(a)	trade,
    quantity, and cash discounts;
	 	 	 
	 	(b)	customary
    and reasonable credits, rebates and chargebacks (including those to managed-care entities and governmental agencies and programs,
    including Medicaid and Medicare), and allowances or credits to customers on account of rejection or returns (including wholesaler
    and retailer returns);
	 	 	 
	 	(c)	freight,
    postage and duties, and transportation charges relating to such Product, including handling and insurance thereto; and
	 	 	 
	 	(d)	sales
    (such as VAT or its equivalent) and excise taxes, other consumption taxes, customs duties and compulsory payments to Governmental
    Authorities and any other governmental charges imposed upon the importation, use or sale of such Product to Third Parties (excluding
    any taxes paid on the income from such sales) to the extent that the Selling Party is not otherwise entitled to a credit or a refund
    for such taxes, duties or payments made.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 5 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Sales
between a Party and its Affiliates shall be excluded from the computation of Net Sales and no payments shall be payable on such sales
except where such Affiliates are end users. If non-monetary consideration is received for a Product, Net Sales shall be calculated based
on the average price charged for such Product during the preceding quarter or, in the absence of such sales, the fair market value of
the Product, as determined by the Parties in good faith. Calculation of Net Sales for purposes of any Co-Packaged Combination Products
shall be as set forth in the applicable Product Schedule.

 

“Nominated
Product” means any of the following that is nominated by JOT for inclusion in this Agreement: (a) a pharmaceutical product,
whether or not containing a JOT Compound; (b) a new dosage strength of an existing Product; (c) a Co-Packaged Combination Product; or
(d) a Fixed-Dose Combination Product that, in each case, (i) contains, subject to acceptance by Aquanova pursuant to Section 3.01, an
Active Ingredient that is not Resveratrol, and (ii) is intended for the pharmaceutical use in respect to the treatment of one of the
Listed Indications.

 

“North
America” means the United States of America, Canada and Mexico, including all of their respective possessions and territories.

 

“Out-of-Pocket
Expenses” means, with respect to activities pursuant to this Agreement, actual expenses paid or payable by either Party or
its Affiliates to Third Parties (other than employees of such Party or its Affiliates) that are specifically identifiable and incurred
to conduct such activities for a Product and have been recorded in accordance with the applicable Accounting Standards.

 

“Patent
Rights” means any and all patents and patent applications, including any divisions, continuations, continuations-in-part, reissues,
re-examinations, renewals, extensions, supplementary protection certificates, and the like of any such patents and patent applications
and all equivalents thereof worldwide.

 

“Product”
means a JOT Product on basis and/or embedding the Formulation created by Aquanova in either of the following types: (a) a Named Product;
or (b) a Nominated Product that is designated as a “Product” pursuant to Section 3.01(b). 

 

“Product
Transaction” means a transaction entered into by JOT with a Third Party involving (a) the grant of a license under the Aquanova
Patent Rights and Aquanova Know How to such Third Party to sell or otherwise Commercialize a Product in a country in the Territory, or
(b) the grant of rights to a Third Party to market, distribute and promote a Product in a country in the Territory, in each case where
JOT has the rights to Commercialize a Product in such country in the Territory.

 

“Product
Transaction Party” means any Third Party that has entered into a written agreement with JOT with respect to a Product Transaction.

 

“Regulatory
Approval” means the permission or consent granted by any relevant Regulatory Authority for the marketing and sale of a Product
in a country or other jurisdiction, including, where applicable pricing or reimbursement approval in such country or other jurisdiction.

 

“Regulatory
Authority” means any Governmental Authority involved in granting approvals for the Development, Manufacture, Commercialization,
marketing or pricing of a Product in a country, including, in the U.S., the FDA.

 

“Regulatory
Filing” means any submission or application made or filed with a Regulatory Authority with the purpose of obtaining a Regulatory
Approval.

 

“Regulatory
Materials” means Regulatory Filings and other submissions, communications, notifications, registrations, and/or other filings
made to or with a Regulatory Authority, but excluding Regulatory Approvals.

 

“ROW”
means all of the countries of the world outside of the North America, and each of their respective possessions and territories.

 

“Royalty
Term” means, on a Product-by-Product and country-by-country basis, the
period of time expiring on the later of (a) 10 years after the First Commercial Sale of such Product in such country, or (b) the first
date that there is no Valid Claim within the Aquanova Patent Rights of such Product, or (c) the date of expiration of all Market
Exclusivity Rights in such country.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 6 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

“Sublicensee”
means (a) in the case of JOT, a Third Party to whom (i) JOT has granted a sublicense under the license granted to it under Section
9.02(a) or in the applicable Product Schedule, to Manufacture, sell or otherwise Commercialize a Product in the Territory; or (ii) granted
rights to market, distribute and promote a Product in the Territory; and (b) in the case of Aquanova, a Third Party to whom Aquanova
has granted a license under the Aquanova Patent Rights or Aquanova Know-How to Manufacture a Product in a country in the Territory.

 

“Technology”
means the technologies currently used by Aquanova in its product formulation and development and any improvements thereto that Aquanova
incorporates into a Product.

 

“Territory”
means the North America and the ROW.

 

“Third
Party” means any person or entity that is not a Party or an Affiliate of a Party.

 

“U.S.”
means the United States of America, including all of its possessions and territories.

 

“Valid
Claim” means, as determined on a country-by-country basis, (a) a claim of a pending patent application that is being prosecuted
in good faith and that has not been abandoned or finally rejected without the right of appeal, provided that such prosecution
has not been ongoing for more than five (5) years from the date such patent application was filed; or (b) a claim of any unexpired issued
patent that shall not have been dedicated to the public, disclaimed nor held revoked, invalid or unenforceable by a court or government
agency of competent jurisdiction in an un-appealed or un-appealable decision.

 

Article
II. 

 

COLLABORATION;
JOINT STEERING COMMITTEE

 

Section
2.01 Collaboration. Subject to the terms and conditions of this Agreement: the Parties seek to collaborate in the Development
and Commercialization of certain pharmaceutical products utilizing Technology for use within the Field; Aquanova will use Commercially
Reasonable Efforts to perform the Formulation Development Activities, initially to support Regulatory Approval in the U.S., with compensation
from JOT for its fees, subject to the definitions of this agreement including e.g. the Product Budget as previously approved by the Parties
as part of the Product Schedule in the JSC; JOT will use Commercially Reasonable Efforts to Develop such Products and seek, initially,
Regulatory Approval in the U.S., and thereafter in the ROW; JOT will own all Regulatory Approvals. JOT will have the sole and exclusive
right to Develop and Commercialize all Products in the Territory.

 

Section
2.02 Establishment of Joint Steering Committee. Within ninety (90) days after the Effective Date, the Parties shall establish
a joint steering committee (the “JSC”) to provide a forum for reviewing, coordinating and discussing the Development
Activities and Commercialization Activities being conducted by each Party with respect to the Products in the Territory. The JSC shall
regularly meet via physical or teleconferencing or online/Internet conferences on a quarterly basis and shall consist of an equal number
of representatives from each Party.

 

Section
2.03 Administration of the JSC. Each Party shall nominate its own representatives to the JSC, provided that such individuals
are appropriately qualified. Each Party nominates an equal number of its representatives to the JSC. The JSC shall each hold at least
one meeting each calendar quarter. The quorum for a meeting of the JSC shall be met only if at least one representative of each Party
is present. The JSC may meet either (a) in person at such locations as the Parties may agree or (b) by audio or video teleconference;
provided that no less than one meeting during each calendar year shall be conducted in person. Other representatives of each Party
involved with a Product may attend meetings upon the prior written consent of the other Party (not to be unreasonably withheld or delayed),
subject to the confidentiality provisions set forth in Section 12.01. Additional meetings of the JSC may also be held with the prior
consent of each Party or as required under this Agreement. Each Party shall be responsible for all of its own expenses incurred in connection
with participating in such meetings.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 7 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Section
2.04 Responsibilities of the JSC. The responsibilities of the JSC shall include (a) prompt development, for JOT’s approval,
of a budget for Formulation Development Activities and Development Activities, if any, to be conducted by or on behalf of Aquanova

 

Section
2.05 With respect to a Product in the Territory based on Aquanova’s good-faith, reasonable estimates and experience (each,
a “Product Budget”); (b) the review and development of Product Specifications for a Named Product or a Nominated Product,
as applicable; (c) the review and development of a Product Schedule for a Named Product or a Nominated Product as applicable; and (d)
discussions with any Party wishing to discontinue a Clinical Trial with respect to a Product pursuant to Section 3.04(c), and (f) discussions
with respect to the supply arrangements contemplated by Sections 7.01 and 7.02. The Parties acknowledge and agree that in no event will
JOT be obligated to pay Aquanova for any Formulation Development or Development expenses or fees or otherwise incurred by Aquanova to
obtain Regulatory Approval in the Territory that are not set forth in any Product Budget nor will Aquanova be required to perform any
Formulation Development or Development if the costs exceed the applicable Product Budget, except to the extent the Parties otherwise
agree in writing. The Parties further acknowledge and agree that the JSC shall have no authority to amend the terms and conditions of
this Agreement. Minutes with resolutions decided shall be taken at each meeting. Such minutes shall be distributed to all JSC participants
within 15 days of each JSC meeting. Decisions of the JSC are made unanimously.

 

Article
III. 

 

DEVELOPMENT

 

Section
3.01 Product Schedule. 

 

	 	(a)	Prior
    to the commencement of any Formulation Development or Development Activities with respect to a Named Product, the Parties shall work
    together, through the JSC, to establish specifications (in each case, “Product Specifications”) for such Named Product.
    Aquanova shall also prepare a Product Budget, together with the JSC, for such Named Product for JOT’s review and approval.
    The Product Specifications, together with the approved Product Budget applicable to such Named Product, shall be mutually agreed
    to in writing by the Parties (each, a “Product Schedule”).
	 	 	 
	 	(b)	JOT
    shall designate a Nominated Product by providing written notice to Aquanova (each, a “Nominated Product Notice”).
    Each Nominated Product is subject to acceptance by Aquanova. Once accepted by Aquanova, the Parties shall work together, through
    the JSC, to establish the Product Specifications for such Nominated Product. Aquanova shall prepare a Product Budget, together with
    the JSC, for such Nominated Product for JOT’s review and approval. The Product Schedule containing the Product Specifications,
    together with the approved Product Budget applicable to such Nominated Product, shall be mutually agreed to in writing by the Parties.
    Upon the mutual agreement in writing by the Parties of a Product Schedule for such Nominated Product, such Nominated Product shall
    be designated a Product.
	 	 	 
	 	 	Each
    Product Schedule shall be handed to the Parties as an original copy for each Party duly signed by both Parties A Product Schedule
    may only be amended upon the mutual written agreement of both Parties. If there is a conflict between the terms and conditions set
    forth in a Product Schedule and the terms and conditions of this Agreement, the terms and conditions of this Agreement shall govern
    unless the Product Schedule expressly refers to the Parties’ intent to alter the terms and conditions of this Agreement with
    respect to a particular provision for purposes of that Product Schedule only.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 8 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Section
3.02 Development Activities. With respect to each Product, JOT shall have the right to oversee and coordinate all Development
Activities in the Territory. Without limiting the foregoing:

 

	 	(a)	Aquanova
    shall conduct Formulation Development for the Products in the Territory to the extent determined in the Product Budget but with the
    restriction in Section 2.04. For clarification reasons, Aquanova is not obliged to perform any Formulation Development to the extent
    that such Formulation Development exceeds the costs determined in the applicable Product Budget except to the extent the Parties
    otherwise agree in writing.
	 	 	 
	 	(b)	Subject
    to Section 3.04, JOT shall use Commercially Reasonable Efforts to Develop the Products and obtain and maintain Regulatory Approval
    for the Products in the Territory. The Parties acknowledge and agree that JOT shall be deemed to be using Commercially Reasonable
    Efforts with respect to a Product to the extent that it is prosecuting an application for Regulatory Approval in the U.S. and that
    JOT shall not have any obligation with respect to the evaluation of any country in the ROW as a territory to Develop and/or Commercialize
    a Product unless and until JOT has received Regulatory Approval for such Product in the U.S. Following JOT’s receipt of Regulatory
    Approval with the FDA with respect to a Product, JOT shall use Commercially Reasonable Efforts to obtain and maintain Regulatory
    Approval for such Product in the ROW. 
	 	 	 
	 	(c)	The
    Parties acknowledge and agree that the Products are development-stage Products and nothing herein shall be construed as a guarantee
    that either Aquanova will successfully Develop the Formulation or that JOT will obtain Regulatory Approval for and successfully Commercialize
    the Products in the Territory. 

 

Section
3.03 Assistance.

 

Each
Party shall, upon the other party’s request, provide reasonable assistance to the other Party in the performance of the Formulation
Development Activities and Development Activities, including the provision of all relevant CMC information, clinical trial protocols
and other clinical information, Regulatory Filings and other information, data, materials and specifications requested by the other Party
to conduct the Formulation Development Activities and Development Activities, in each case, to the extent such information or materials
is Controlled by such Party. JOT shall at all times cooperate with Aquanova with respect to the Formulation Development of the Products
at JOT’s expense.

 

Section
3.04 Clinical Studies.

 

	 	(a)	JOT
    shall design all Clinical Trial protocols and conduct all Clinical Trials to obtain Regulatory Approval for the Products in the Territory
    at JOT’s expense. 
	 	 	 
	 	(b)	JOT
    shall provide Aquanova with regular status reports on each Clinical Trial conducted by JOT. Each such report shall include the data,
    results, adverse event reporting and other information identified in the applicable Product Schedule, to the extent available. In
    addition, following completion of each Clinical Trial conducted by JOT, JOT shall maintain a file for each Clinical Trial containing
    such data, results, information, reports, records, correspondence and document as identified in the applicable Product Schedule (collectively,
    the “Clinical Trial Information”).
	 	 	 
	 	(c)	Notwithstanding
    any provision in this Agreement or a Product Schedule to the contrary, JOT may, upon notice to Aquanova, discontinue its obligations
    to conduct any Clinical Trial with respect to a Product, to the extent that based on clinical and scientific data, JOT reasonably
    concludes and reasonably demonstrates to Aquanova that such Product would not obtain Regulatory Approval in the Territory or it is
    not commercially reasonable to seek such approval. Following such notice, the Parties shall determine, through the JSC, whether a
    replacement Clinical Trial is appropriate. Fees already paid to Aquanova by JOT for the Formulation Development are not to be refunded.
    

 

Section
3.05 Subcontracting. Each Party have the right to subcontract any of its obligations under this Article III with prior written
consent of the other Party..

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 9 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Section
3.06 Recordkeeping and Reporting. Each Party shall maintain, or cause to be maintained, for at least five (5) years after
completion of all Development Activities and Formulation Development Activities hereunder or for such longer period as may be required
by Applicable Law or its internal standard operating procedures, records of Development Activities performed by or on behalf of such
Party in sufficient detail and in good scientific manner as appropriate for patent and regulatory purposes and as required by Applicable
Laws, which records shall fully and properly reflect all work done and results achieved by or on behalf of such Party in the performance
of such Development Activities. Each Party shall keep the other Party appropriately informed on an ongoing basis, through the JSC, or
otherwise, of the status and results of the Development Activities being performed and/or completed by or on behalf of such Party, including
by providing a written progress report fourteen (14) days in advance of each regularly scheduled JSC meeting describing in appropriate
detail the Development Activities conducted by or on behalf of such Party, including any difficulties and unexpected circumstances encountered
and any other relevant matters, in each case since the last such progress report.

 

Section
3.07 Reimbursement of Expenses. JOT shall reimburse any of Aquanova ́s Out-of-Pocket Expenses in accordance with the
applicable Product Budget relating to the conduct of the Development Activities and Formulation Development Activities in the Territory,
plus ten percent (10%) of such amount, as and when incurred by Aquanova, provided that Aquanova provides satisfactory written
support information and evidence of such Out-of-Pocket Expenses incurred.

 

Section
3.08 Compliance; Debarment.

 

	 	(a)	Each
    Party shall conduct the Development Activities (including regulatory matters) and Formulation Development Activities in a good scientific
    manner. Each Party agrees that each Clinical Trial to be conducted that is required to be posted pursuant to Applicable Law or applicable
    industry codes, including the PhRMA Code, on clinicaltrials.gov or any other similar registry shall be so posted. 
	 	 	 
	 	(b)	In
    the course of conducting the Development Activities and Formulation Development Activities of the Products, neither Party shall use
    any employee, agent or independent contractor who has been debarred by any Regulatory Authority, or to such Party’s knowledge,
    is the subject of debarment proceedings by a Regulatory Authority or has been convicted pursuant to Section 306 of the FDC Act or
    any foreign equivalent thereof. 

 

Article
IV. 

 

REGULATORY
MATTERS

 

Section
4.01 Regulatory Matters. JOT shall be responsible for using Commercially Reasonable Efforts to obtain Regulatory Approvals
for all of the Products in the Territory. All Regulatory Filings and Regulatory Approvals relating to a Product in the Territory shall
be filed by JOT and JOT shall own all rights, title and interest to the Regulatory Filings and Regulatory Approvals, subject to the licenses
set forth in Section 4.02. JOT shall use Commercially Reasonable Efforts to seek orphan drug designation by the FDA in accordance with
21 CFR 316 for each Product for each of the Listed Indications.

 

Section
4.02 Filing. The Parties shall discuss through the JSC the type of Regulatory Filing (such as a New Drug Application pursuant
to Section 505(b)(2) of the FDA Act) to be made to obtain Regulatory Approval for the Products in the Territory. Notwithstanding the
foregoing, JOT shall have the sole right to determine the type of Regulatory Filing to be made to obtain Regulatory Approval for the
Products in the Territory.

 

Section
4.03 Communications with Regulatory Authorities.

 

	 	(a)	JOT
    shall be solely responsible for any communications with Regulatory Authorities occurring or required in connection with obtaining
    or maintaining any Regulatory Approvals for a Product in the Territory. Upon the reasonable request of JOT, Aquanova shall assist
    JOT at Aquanova’s expense to address requests from and communications to Regulatory Authorities applicable to Aquanova’s
    activities conducted with respect to a Product, including data and information Controlled by Aquanova.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 10 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Section
4.04 Adverse Drug Experiences; Pharmacovigilance.

 

	 	(a)	To
    the extent that JOT receives any information regarding an adverse drug experience related to a Product or any applicable JOT Compound
    or JOT Product (even if a different formulation than the Product), JOT shall promptly notify Aquanova and provide Aquanova with such
    information as is required to understand the nature and circumstances of the adverse drug experience. No later than one Business
    Day after its occurrence or at Aquanova’s request, as applicable, JOT shall provide to Aquanova (i) all serious adverse event
    reports received or made by JOT with respect to a JOT Product; and (ii) all adverse event reports and other information with respect
    to a JOT Product to the extent required to be reported by Aquanova.
	 	 	 
	 	(b)	To
    the extent that Aquanova receives any information regarding an adverse drug experience related to a Product or any product using
    the Technology (even if using a different Active Ingredient than the Product), Aquanova shall promptly notify JOT and provide JOT
    with such information as is required to understand the nature and circumstances of the adverse drug experience. No later than ten
    (10) Business Days after its occurrence or at JOT’s request, as applicable, Aquanova shall provide to JOT all serious adverse
    event reports received or made by Aquanova with respect to any product using the Technology other than the Product and all adverse
    event reports and other information with respect to any product using the Technology other than the Product to the extent such report
    is required to be reported by JOT. JOT shall similarly provide to Aquanova all such serious and other adverse event reports and other
    information relating to the Product and allow it to provide such reports and information to Regulatory Authorities and Third Parties
    involved in the sale of other products using the Technology.
	 	 	 
	 	(c)	Promptly
    after the date of execution of such Product Schedule, but no later than the date of initiation of a Clinical Trial for the applicable
    Product, the Parties shall enter into a pharmacovigilance agreement, if applicable and required, that shall govern each Party’s
    respective obligations with respect to adverse event reporting, monitoring, maintenance of safety databases and submissions to Regulatory
    Authorities and other similar obligations with respect to such Product (a “Pharmacovigilance Agreement”). 
	 	 	 
	 	(d)	JOT
    shall be responsible for all adverse event reporting obligations with respect to a Product in the Territory. JOT shall maintain a
    global, electronic database of all adverse event reports relating to a Product on behalf of the Parties at JOT’s expense. 

 

Article
V. 

 

COMMERCIALIZATION

 

Section
5.01 Diligence in the Territory. JOT shall use Commercially Reasonable Efforts to Commercialize each Product in the Territory,
and shall bear all costs incurred by or on behalf of JOT and its Affiliates in conducting such Commercialization activities.

 

Section
5.02 JOT Reporting. JOT shall keep the JSC fully informed regarding the progress and results of Commercialization activities
for the Products in the Territory, including an annual review of results versus goals. JOT shall provide a written progress report ten
(10) days in advance of each regularly scheduled JSC meeting describing in appropriate detail the Commercialization Activities conducted
by or on behalf of JOT and its Affiliates and Sublicensees, including any difficulties and unexpected circumstances encountered, its
anticipated Net Sales for each Product for the following twelve (12) month period and any other relevant matters, in each case since
the last such progress report.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 11 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Article
VI.

PAYMENTS

 

Section
6.01 Payments by JOT in the Territory.

 

	 	(a)	 	Fixed
    payments:
	 	 	 	 
	 	 	(i)	Kick
    off Payment. In consideration of the licenses and other rights granted to JOT hereunder, JOT shall pay to Aquanova a one-time,
    non-refundable, non-creditable payment of Twenty Thousand U.S. Dollars ($20,000) within 30 days of Aquanova providing all necessary
    product information for CMC purposes available to Aquanova of an, finally by both Parties, accepted formulation for the Product.
    

 

Annual
fees: JOT shall pay to Aquanova a non-refundable, non-creditable payment of Seventy Five Thousand U.S. Dollars ($75,000) per
each 12 months period following the date of the final acceptance of the formulation by both Parties and ending in the year of the MAA
approval.

 

	 	(b)	Milestones.
    In further consideration of the licenses and other rights granted to JOT hereunder, JOT shall pay Aquanova the following amounts
    after the first achievement by JOT or its Affiliates or Sublicensees, as the case may be, of each of the following milestones (each,
    a “Milestone”): 
	 	 	 
	 	 	Upon
    the receipt of approval of the MAA in each country of the Territory, e.g. the U.S., European Union, and Japan, for the first Product
    in each Listed Indication, Two Hundred Thousand US Dollars ($200,000) (e.g. up to a total of $600,000 if each such jurisdiction
    as example mentioned before approves one Product for each of the Listed Indications) and
	 	 	 
	 	(c)	Payment.
    Each Milestone payment shall be payable by JOT to Aquanova within forty-five (45) days after achievement of the applicable Milestone.
	 	 	 
	 	(d)	Royalties.
    For the duration of the Royalty Term for a Product, JOT shall pay to Aquanova a royalty equal to (a) five percent (5%) of the Net
    Sales in the U.S. for the immediately prior calendar quarter no later than forty-five (45) days after the end of each calendar quarter
    during the Royalty Term. Accompanying each royalty payment, JOT shall submit a statement to Aquanova for the immediately prior calendar
    quarter, which shall set forth the total amount of Net Sales for each Product in each country in the Territory during the calendar
    quarter, and the calculation of royalties due on such Net Sales (each, a “Territory Royalty Statement”).
	 	 	 
	 	(e)
    	Optional
    Royalty payment: Each party has the option to decide and demand, that JOT pays Aquanova a one-time payment of $3 million
    within 180 days of a US Marketing approval of a Product. All Royalties according to 6.01(d) will thereafter be reduced to 1.25% in
    case the optional royalty payment is made by JOT. 

 

Section
6.02 Manner of Payment. All payments from a Party to the other Party shall be made by wire transfer in U.S. Dollars to the
credit of such bank account as may be designated by the other Party in this Agreement or in writing to such Party. Any payment which
falls due on a date which is not a Business Day may be made on the next succeeding Business Day. Any payments or portions thereof due
hereunder which are not paid on the date such payments are due under this Agreement shall bear interest at the lower of (i) 4% over the
overnight LIBOR rate in effect on the due date, or (ii) the maximum rate permitted by Applicable Law, calculated on the number of days
such payment is delinquent, compounded monthly. Costs of wire transfer are borne by the Party that made the payment, except for any excess
fees charged by the receiving party’s bank.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 12 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Section
6.03 Currency Conversion. For any currency conversion required in determining the amount of any payment due, such conversion
shall be made at the prevailing commercial rate of exchange for purchasing the currency into which an amount is to be converted as set
forth in the European Central Bank on the day that is the last business day of the applicable quarterly period for any payments made
pursuant to this Agreement.

 

Section
6.04 Tax Withholding. Each Party will pay any and all taxes levied on account of any payments made to it under this Agreement.
If any taxes are required to be withheld by a Party, such Party will: (a) deduct such taxes from the payment made to the other Party;
(b) timely pay the taxes to the proper taxing authority; (c) send proof of payment to the Party; and (d) reasonably assist the other
Party in its efforts to obtain a credit for such tax payment. Each Party agrees to reasonably assist the other Party in lawfully claiming
exemptions from and/or minimizing such deductions or withholdings under double taxation laws or similar circumstances.

 

Section
6.05 Records and Audit Rights.

 

	 	(a)	Financial
    Records. The Parties shall keep complete and accurate books and records with respect to activities undertaken pursuant to
    this Agreement in accordance with Accounting Standards in sufficient detail to support calculations of all payments that may become
    due hereunder. The Parties will keep such books and records for at least three (3) years following the end of the calendar year to
    which they pertain.
	 	 	 
	 	(b)	Audit
    Rights. Aquanova shall have the right to appoint an internationally-recognized independent accounting firm (which is reasonably
    acceptable to the other Party) (the “Auditor”) to audit the relevant books and records of JOT and the correctness
    of any payments made or required to be made to or by JOT pursuant to the terms of this Agreement, in each case upon reasonably written
    notice to JOT. Before beginning its audit, the Auditor shall execute an undertaking acceptable to JOT by which the Auditor shall
    keep confidential all information reviewed during such audit. The Auditor shall have the right to disclose to Aquanova only its conclusions
    regarding any payments owed under this Agreement. JOT shall make its books and records available for inspection by such Auditor during
    regular business hours at such place or places where such books and records are customarily kept, upon receipt of reasonable advance
    notice from Aquanova, solely to verify the accuracy of the payments to be made hereunder. The Auditor may only audit the books and
    records of JOT from the two (2) calendar years prior to the calendar year in which the audit request is made. Such inspection right
    shall not be exercised more than once in any calendar year and not more frequently than once with respect to books and records covering
    any specific period of time. All information received and all information learned by Aquanova in the course of any audit or inspection
    shall constitute Confidential Information of JOT. Aquanova shall pay for the cost of the Auditor, as well as its own expenses associated
    with enforcing its rights with respect to any payments hereunder, except that in the event there is any upward adjustment in aggregate
    amounts payable for any calendar year shown by such audit of more than five percent (5%) of the amount paid, then, in addition to
    paying the full amount of any underpayment, JOT shall reimburse Aquanova for all reasonable costs and expenses incurred by Aquanova
    in connection with that audit. In the event that such audit reveals an underpayment by JOT, JOT shall promptly pay to Aquanova the
    amount of such underpayment. 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 13 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Article
VII. 

DEVELOPMENT
AND COMMERCIALIZATION MANUFACTURE AND SUPPLY

 

Section
7.01 Supply of JOT Compound and Active Ingredients for Development. 

 

	 	(a)	JOT
    shall supply to Aquanova all of the requirements of Aquanova and its Affiliates and subcontractors for JOT Compounds for each Product
    in such amounts as agreed in the Product Schedule for use in the conduct of Aquanova’s Formulation Development Activities in
    the Territory. The Parties shall cooperate with each other in an effort to source, in the most efficient and economical manner, the
    Active Ingredients (other than the JOT Compounds) for each Product in such amounts as agreed by the JSC for use in the conduct of
    Aquanova’s Formulation Development Activities in the Territory. Notwithstanding the foregoing, such supply of JOT Compounds
    and Active Ingredients shall be supplied to Aquanova for Formulation Development Activities at no cost to Aquanova. 
	 	 	 
	 	(b)	The
    Parties shall cooperate with each other in an effort to source, in the most efficient and economical manner, the Active Ingredients
    (other than the JOT Compounds) for each Product in such amounts as agreed by JOT for use in the conduct of JOT’s Development
    Activities in the Territory.

 

Section
7.02 Supply of JOT Compound, Active Ingredients and Products for Commercialization.

 

The
Parties shall cooperate with each other in an effort to source, in the most efficient and economical manner, the JOT Compounds, Active
Ingredients and Product for Commercialization pursuant to supply arrangements that may involve third party manufacturers and shall be
the subject of a separate agreement, which agreement shall be consented to by the Parties, which consent shall not be unreasonably withheld.
Aquanova has clearly expressed that it does not fit their operation to apply for FDA compliance and be the designated Product Manufacturer.
Aquanova therefore agrees to actively participate in the selection, required transfer of Formulation related required Know-How and final
approval of a Product Manufacturer that meets all regulatory and other necessary standards to solely manufacture a Product in the Field.
The parties understand and agree that such selection, transfer of Formulation related required Know-How and decision on a Product Manufacture
must not negatively effect / lower the payments from JOT to Aquanova such as e.g. fees, milestone payments or royalties as outlined in
section 6 of this Agreement.

 

Article
VIII. 

 

COMPLIANCE;
OTHER COVENANTS

 

Section
8.01 Compliance with Law. Each Party shall perform its obligations under this Agreement in accordance with all Applicable
Law, including the Good Practices. No Party shall, or shall be required to, undertake any activity under or in connection with this Agreement
which violates, or which it believes, in good faith, may violate, any Applicable Law.

 

Section
8.02 Permits and Licenses. Each of the Parties shall maintain at its own expense the necessary licenses and permits for the
Development, Manufacture, use and Commercialization of the Products as required by Applicable Law and to be able to perform its obligations
assigned to it under this Agreement. Each Party obliges its Affiliates, Sublicensees and subcontractors to fulfil the aforementioned
obligation.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 14 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Section
8.03 Exclusivity.

 

	 	(a)	During
    the term of this Agreement, and to the fullest extent allowed under Applicable Law, JOT shall not engage in any activity, on its
    own or with any Third Parties, regarding Nominated Products, relating to the Development, Manufacture, Commercialization or granting
    licenses of the (a) competitive formulation(s) of the Active Ingredient(s) other than the Aquanova Formulation(s) according to this
    Agreement for pharmaceutical products in the Territory, except as expressly permitted in this Agreement. JOT will oblige its Affiliates
    to fulfil these requirements accordingly.
	 	 	 
	 	(b)	During
    the term of this Agreement, and to the fullest extent allowed under Applicable Law, Aquanova shall not engage in any activity, on
    its own or with any Third Parties, relating to the Development, Manufacture, Commercialization or granting licenses of (a) alternative
    formulation(s) of the Active Ingredient(s) other than the Formulation(s) according to this Agreement in for pharmaceutical products
    in the Territory, except as expressly permitted in this Agreement. Aquanova will oblige its Affiliates to fulfil these requirements
    accordingly. 

 

Section
8.04 Non-compete.

 

	 	(a)	To
    the fullest extent allowed under Applicable Law, JOT shall not engage in any activity, on its own or with any Third Parties, relating
    to the Development, Manufacture, Commercialization or granting licenses of any products that will compete with any Aquanova products
    except as expressly permitted in this Agreement. JOT will oblige its Affiliates to fulfil these requirements accordingly.
	 	 	 
	 	(b)	To
    the fullest extent allowed under Applicable Law, Aquanova shall not engage in any activity, on its own or with any Third Parties,
    relating to the Development, Manufacture, Commercialization or granting licenses of any products that will compete with any JOT products
    in the Field except as expressly permitted in this Agreement. Aquanova will oblige its Affiliates to fulfil these requirements accordingly.
    

 

Article
IX. 

 

GRANT
OF LICENSES

 

Section
9.01 License Grants from Aquanova to JOT. Except to the extent required to conduct the Formulation Development Activities,
Aquanova hereby grants to JOT an exclusive license to Develop, Manufacture, Sub-license and Commercialize the Products covered by the
Joint Patent Rights and Know-How in the Territory for use in the Field. For the avoidance of doubt, this license does not comprise any
other fields of use of the Joint Patent Rights, e.g. the field of dietary supplements, cosmetics, food or beverages. If the Parties want
to extend this Agreement on these fields of use, they will conclude a further agreement as an amendment of this Agreement in written
form.

Aquanova further hereby grants JOT an exclusive license to Develop, Manufacture, Sub-license and Commercialize the Products covered by
the German Utility model DE 20 2009 016 292 U1 (Appendix 4) for use in the Field. This license is restricted to the use of the emulsifier,
which is subject of the utility model, for a solubilisate comprising the API.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 15 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Section
9.02 Sublicenses and Distributorships by JOT.

 

	 	(a)	Sublicenses.
    The licenses granted to JOT pursuant to Section 9.01 includes the right to sublicense. Each such sublicense shall (i) be subject
    to an according written agreement between the parties subject and subordinate to, and consistent with, the terms and conditions of
    this Agreement that are applicable to such sublicense; (ii) not in any way diminish, reduce or eliminate any of JOT’s obligations
    under this Agreement, including any obligation to use Commercially Reasonable Efforts to Commercialize any Product (but efforts of
    any Sub-licensee in such regard shall be considered efforts of JOT) and (iii) be concluded after the prior written consent by Aquanova.
    JOT shall remain responsible for its obligations under this Agreement and for the performance of its Affiliates and Sublicensees.
    JOT shall provide Aquanova a copy of each such agreement, which may be redacted of all information not reasonably required for Aquanova
    to verify that such agreement complies with this Section 10.02(a).
	 	 	 
	 	(b)	Distributorships.
    Aquanova acknowledges and agrees that JOT shall have the right to appoint wholesalers and physical distributors under this Agreement
    without the prior written consent of Aquanova. JOT shall promptly notify Aquanova of the appointment of any such Third Party and
    shall remain primarily responsible for all of its obligations hereunder.

 

Section
9.03 License Grants from JOT to Aquanova. 

 

	 	 	JOT
    hereby grants to Aquanova an exclusive license, with the right to sublicense, under the JOT Patent Rights, the JOT Know-How, the
    Product Inventions and the Product Invention Patent Rights to conduct Formulation Development Activities and Manufacturing in the
    Territory. For the avoidance of doubt, this license does not comprise any rights for Aquanova and it’s affiliates and partners
    to develop, manufacture, distribute and sell any products competing with JOT Products in the Field.
	 	 	 
	 	(a)	No
    Implied Licenses. 
	 	 	 
	 	 	Except
    as explicitly set forth in this Agreement, neither Party grants to the other Party any license, express or implied, under its Patent
    Rights, Know-How or any other intellectual property rights. Neither Party shall knowingly use or practice any of the other Party’s
    intellectual property rights licensed to it under this Agreement except for the purposes expressly permitted in the applicable license
    grant.
	 	 	 
	 	(b)	Disclosure
    of JOT Know-How. 
	 	 	 
	 	 	As
    soon as reasonably practicable, and in any event within ninety (90) days after the date of the establishment of a Product Schedule,
    JOT shall disclose to Aquanova all JOT Know-How in existence as of such date relating to the applicable Product. JOT shall deliver
    as promptly as practicable thereafter all items of such JOT Know-How that are necessary or useful for the Formulation Development,
    Development, Manufacture, use and/or Commercialization of the Products in the Territory (such disclosure, the “Technology
    Transfer”). 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 16 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Article
X. 

 

INTELLECTUAL
PROPERTY

 

Section
10.01 Ownership of Inventions.

 

	 	(a)	Aquanova
    exclusively filed the patent No. PCT/EP2016/063579 and has through JOT acquired know how regarding specifications of the formulation
    and processing of the Active Ingredient prior to the signing of this Agreement. The Parties has agreed that JOT and Aquanova, through
    an assignment of the co-inventor Marshall Hayward, shall jointly own such patent. JOT is obliged to, from the date of this agreement,
    pay for all filing costs and maintain the patents and applications as listed in Appendix 3 during the term of the Agreement. JOT
    shall take the appropriate measures regarding PCT filing and future national filings required to protect the Joint Patent Rights
    in the territory. In case of a lack of payment by JOT for these costs, Aquanova is not obliged to take the necessary steps to maintain
    the patents and application listed in Appendix 3. JOT shall notify Aquanova six months prior to the commencement of the national
    phase of the patent applications in Appendix 3 about the costs for filing national patent applications. JOT shall notify Aquanova,
    in writing, about the countries in which the listed patent applications in Appendix 3 will be filed latest three months before the
    commencement of the national phase. Aquanova has the option to add national applications that JOT does not plan to file applications
    in. Aquanova will be responsible for the cost for any such additional filing.
	 	 	 
	 	(b)	JOT
    remains the sole proprietor of all JOT Patent Rights and JOT Know How regardless of any licenses that may be granted to Aquanova
    under the terms and conditions of this Agreement.
	 	 	 
	 	(c)	Product
    inventions: Inventions solely made by employees of JOT during the course of performing activities under this Agreement and that relate
    to a Product to be used in the Field (“Product Inventions”) will be claimed by JOT and filed in the name of JOT as an
    Intellectual property right (“New Product Intellectual Property Right”). JOT will inform Aquanova about the filing
    of such Intellectual Property Rights.
	 	 	 
	 	(d)	Product
    Inventions solely made by employees of Aquanova during the course of performing activities under this Agreement will be claimed by
    Aquanova and filed in the name of Aquanova as a New Intellectual Property Right. Aquanova will transfer such New Intellectual Property
    Right to JOT for a consideration of 1 US Dollar.
	 	 	 
	 	(e)	Product
    Inventions jointly made by employees of JOT and Aquanova during the course of performing activities under this Agreement will be
    claimed by both Parties and filed in the name of JOT as a New Intellectual Property Right. Aquanova will transfer its part of the
    application of such New Intellectual Property Right or if a transfer of an application is not possible due to legal grounds its part
    of such registered New Intellectual Property Right to JOT for a consideration of 1 US Dollar.
	 	 	 
	 	(f)	In
    case JOT decides not to file for a New Intellectual Property Right according to Section 10.01 (c) and (e) or to give up any New Intellectual
    Property Right that has been filed or registered according to Section 10.01 (c) and (e), JOT will inform Aquanova and offer to transfer
    this New Intellectual Property Right to Aquanova for a consideration of 1 US Dollar.
	 	 	 
	 	(g)	During
    the term of this Agreement each Party that holds New Intellectual Property Rights or Know How that resulted during the course of
    performing activities under this Agreement and that relates to a Product to be used in the Field grants the other Party a non-exclusive
    license of the New Intellectual Property Rights or Know How for the purpose of further research and development at no cost.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 17 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Section
10.02 Disclosure of Inventions; Aquanova Cooperation. Aquanova shall promptly disclose to JOT all Product Inventions conceived,
generated, discovered or made by or on behalf of Aquanova, its Affiliates or any of their respective Sublicensees or subcontractors,
including all invention disclosures or other similar documents. Aquanova agrees to cooperate reasonably with JOT in the preparation,
filing, prosecution and maintenance of any Product Inventions, including any Patent Rights or other intellectual property rights relating
thereto. Such cooperation includes executing all papers and instruments, or requiring employees or others to execute such papers or instruments,
so as to effectuate the ownership of such Product Inventions by JOT and to enable the filing, prosecution, maintenance and extension
thereof in any country. JOT shall be similarly obligated in respect of Novasol® Inventions.

 

Section
10.03 Enforcement of Joint Patent Rights. If a Party learns that any of the Joint Patent Rights are infringed or misappropriated
by activities of a Third Party relating to a Product in any country in the Territory, such Party shall promptly notify in writing the
other Party hereto. JOT shall have the initial right to enforce the Joint Patent Rights in the Territory and Aquanova agrees to join
such proceeding, at JOT’s expense, if required by Applicable Law for JOT to bring such action. If JOT fails to initiate a suit
to enforce such Joint Patent Rights relating to a Product against such a Third Party in the Territory within ninety (90) days after notification
of such infringement or declines to initiate such suit, then Aquanova may initiate such suit against such infringement in the name of
Aquanova and at the expense of Aquanova in the Territory; provided that JOT agrees to join such proceeding, at Aquanova’s
expense, if required by Applicable Law for Aquanova to bring such action. The Party bringing any such claim, suit or proceeding (the
“Enforcing Party”) pursuant to this Section 10.03, shall keep the other Party hereto reasonably informed of the progress
of any such claim, suit or proceeding. Without the prior written consent of the other Party, neither Party shall enter into a settlement
with a Third Party involving such Joint Patent Rights in any manner that would negatively impact such intellectual property or that would
limit or restrict the ability of either Party to Commercialize the Products anywhere in the Territory or the ROW. Aquanova and JOT shall
first recover their respective actual out-of-pocket expenses associated with any litigation or settlement thereof from any recovery made
by any Party. Any excess amount recovered shall be divided in the following manner: to JOT to cover any lost profits as a result of such
infringement or misappropriation, and then seventy-five percent (75%) to the Enforcing Party and twenty-five percent (25%) to the other
Party. JOT shall have the sole right to enforce the Joint Patent Rights in the ROW.

 

Section
10.04 Enforcement of New Product Intellectual Patent Rights.

 

	 	(a)	If
    a Party learns that any of the New Product Invention Patent Rights are infringed or misappropriated by activities of a Third Party
    relating to a Product in any country in the Territory, such Party shall promptly notify in writing the other Party hereto. JOT shall
    have the initial right (but not the obligation) to enforce the New Product Invention Patent Rights in the Territory and Aquanova
    agrees to join such proceeding, at JOT’s expense, if required by Applicable Law for JOT to bring such action. If JOT fails
    to initiate a suit to enforce such New Product Invention Patent Rights relating to a Product against such a Third Party in the ROW
    within ninety (90) days after notification of such infringement or declines to initiate such suit, then Aquanova may initiate such
    suit against such infringement in the name of Aquanova and at the expense of Aquanova in the ROW; provided that JOT agrees
    to join such proceeding, at Aquanova’s expense, if required by Applicable Law for Aquanova to bring such action. 
	 	 	 
	 	(b)	The
    Enforcing Party pursuant to this Section 10.04, shall keep the other Party hereto reasonably informed of the progress of any such
    claim, suit or proceeding. Without the prior written consent of the other Party, neither Party shall enter into a settlement with
    a Third Party involving such Product Invention Patent Rights in any manner that would negatively impact such intellectual property
    or that would limit or restrict the ability of either Party to Commercialize the Products anywhere in the Territory or the ROW. Aquanova
    and JOT shall first recover their respective actual out-of-pocket expenses associated with any litigation or settlement thereof from
    any recovery made by any Party. Any excess amount recovered shall be divided in the following manner: to JOT to cover any lost profits
    as a result of such infringement or misappropriation, and then seventy-five percent (75%) to the Enforcing Party and twenty-five
    percent (25%) to the other Party. 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 18 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Section
10.05 Infringement Claims. If the Development, Manufacture, use or Commercialization of a Product in the Territory results
in any claim, suit or proceeding alleging patent infringement or misappropriation against Aquanova or JOT, such Party shall promptly
notify in writing the other Party hereto. If JOT is named as a party to such claim, suit or proceeding, or if JOT intervenes, at its
own expense and through counsel of its own choice, in any such claim, suit or proceeding initiated against Aquanova (which intervention
Aquanova will not oppose), JOT shall have the right to control the defense and settlement of such claim, suit or proceeding, at its own
expense, using counsel of its own choice. No Party shall enter into any agreement that makes any admission regarding (a) wrongdoing on
the part of the other Party, or (b) the invalidity, unenforceability or infringement of any Patent Rights, without the prior written
consent of the other Party. The Parties shall cooperate with each other in connection with any such claim, suit or proceeding and shall
keep each other reasonably informed of all material developments in connection with any such claim, suit or proceeding.

 

Section
10.06 Third Party Licenses. If the Development, Manufacture or Commercialization of Product by JOT, its Sublicensees or any
of its or their respective Affiliates hereunder infringes or misappropriates any Patent Rights or other intellectual property right of
a Third Party, such that JOT, its Sublicensees or any of its or their respective Affiliates cannot Develop, Manufacture or Commercialize
the Product as permitted hereunder without infringing the Patent Rights or intellectual property right of such Third Party, then JOT
(or its Sublicensees or any of its or their respective Affiliates) shall have the first right, but not the obligation, to take the lead
in negotiating the terms of an appropriate license from such Third Party, provided that if JOT (or its Sublicensees or any of
its or their respective Affiliates) does not take such lead, then Aquanova may do so; provided further, that the negotiating Party
shall obtain the written consent of such other Party prior to entering into any such license, such consent not to be unreasonably withheld
or delayed. Irrespective of the Party that actually obtains such license, JOT shall be entitled to deduct from royalties and other amounts
it would otherwise owe to Aquanova pursuant to Section 6.01 following the date after the Party obtains such license an amount equal to
the lesser of the dollar amount of the royalties or consideration paid to the owners pursuant to such license. In case no license can
be obtained from a third party by either of the Parties the Product(s) effected shall be terminated from this agreement in respect to
this specific Product in a specific country. Payments already made for this Product, will not be refunded. The Agreement as such will
be continue, until not terminated according to Section 14.

 

Section
10.07 Trademarks. Each Party’s responsibilities with respect to the registration, maintenance and defense of all trademarks,
logos and trade dress (the “Trademarks”) for use in connection with the Manufacture, use and Commercialization of
a Product in the Territory shall be as set forth in a separate agreement between the Parties

 

Article
XI. 

 

REPRESENTATIONS,
WARRANTIES & COVENANTS

 

Section
11.01 Mutual Representations and Warranties. Each Party warrants and represents to the other that as of the Effective Date:

 

	 	(a)	it
    has the full right and authority to enter into this Agreement;
	 	 	 
	 	(b)	to
    the best of its knowledge at the date of signing this Agreement, there are no existing or threatened actions, suits or claims pending
    against it with respect to its right to enter into and perform its obligations under this Agreement;
	 	 	 
	 	(c)	to
    the best of its knowledge at the date of signing this Agreement, there is nothing in any Third Party agreement or understanding,
    written or oral, entered into or agreed to by such Party, that, in any way, will preclude such Party’s ability to perform all
    of the obligations undertaken by it hereunder, and that it will not enter into any agreement after the Effective Date under which
    such performance would be precluded; 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 19 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

	 	(d)	it
    is not a party to any agreement or arrangement with any Third Party or under any obligation or restriction agreement (including any
    outstanding order, judgment or decree of any court or administrative agency) which in any way limits or conflicts with its ability
    to fulfill any of its obligations under this Agreement; 
	 	 	 
	 	(e)	this
    Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms. The execution, delivery and
    performance of this Agreement by such Party does not violate any law or regulation of any court, governmental body or administrative
    or other agency having jurisdiction over it; and 
	 	 	 
	 	(f)	it
    is entitled to grant the rights and licenses granted to the other Party under Section 4.03 and Article X; 
	 	 	 
	 	(g)	it
    has not entered into any licensing or other agreement with any Third Party in conflict with the rights and licenses granted to the
    other Party under Section 4.03 and Article X;

 

Section
11.02 Aquanova Representations and Warranties. Aquanova represents and warrants that as of the Effective Date:

 

	 	(a)	to
    the best of its knowledge at the date of signing this Agreement, there are no existing or threatened actions, suits or claims pending
    against Aquanova with respect to (i) the Joint Patent Rights or (ii) its right to enter into and perform its obligations under this
    Agreement;
	 	 	 
	 	(b)	Aquanova
    has no knowledge at the date of signing this Agreement from which it could reasonably conclude that the Joint Patent Rights are invalid
    or unenforceable; and
	 	 	 
	 	(c)	to
    the best of its knowledge at the date of signing this Agreement the Joint Patent Rights and Aquanova Know-How licensed or sublicensed
    to JOT pursuant to this Agreement has not been obtained by Aquanova or its Affiliates (or its or their predecessors-in-interest)
    in violation of any contractual or fiduciary obligation owed by any of them to a Third Party or by misappropriation of the trade
    secrets of any Third Party. 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 20 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Section
11.03 JOT Representations and Warranties. JOT represents and warrants that as of the Effective Date:

 

	 	(a)	to
    the best of its knowledge at the date of signing this Agreement, there are no existing or threatened actions, suits or claims pending
    against JOT with respect to (i) the JOT Know-How or (ii) its right to enter into and perform its obligations under this Agreement;
    and
	 	 	 
	 	(b)	to
    the best of its knowledge at the date of signing this Agreement the JOT Know-How licensed or sublicensed to Aquanova pursuant to
    this Agreement has not been obtained by JOT or its Affiliates (or its or their predecessors-in-interest) in violation of any contractual
    or fiduciary obligation owed by any of them to a Third Party or by misappropriation of the trade secrets of any Third Party. 

 

Section
11.04 No Other Representations or Warranties. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES
WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT
IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, ALL REPRESENTATIONS AND WARRANTIES, WHETHER
ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED.

 

Article
XII. 

 

CONFIDENTIALITY
AND EXCHANGE OF INFORMATION

 

Section
12.01 Confidential Information. All Confidential Information disclosed by a Party or its Affiliates under this Agreement (including
any Confidential Information developed or created by a Party under this Agreement) will be maintained in confidence and otherwise safeguarded
by the recipient Party during the Term and for three (3) years thereafter. The recipient Party may only use the Confidential Information
for the purposes of this Agreement and pursuant to the rights granted to the recipient Party under this Agreement. Each Party shall hold
as confidential such Confidential Information of the other Party or its Affiliates in the same manner and with the same protection as
such recipient Party maintains its own confidential information, and in any event with no less than reasonable care. A recipient Party
may only disclose Confidential Information of the other Party to employees, representatives, agents, Sublicensees, subcontractors, consultants
and advisers of the Party and its Affiliates to the extent reasonably necessary for the purposes of, and for those matters undertaken
pursuant to, this Agreement; provided that such Persons are bound to abide by non–disclosure obligations at least as strict as
with those set forth in this Article XII. Notwithstanding the foregoing sentence, Confidential Information shall exclude any information
or materials that:

 

	 	(a)	was
    already known to the recipient Party before receipt of such information under this Agreement;
	 	 	 
	 	(b)	was
    or is independently developed by or for the recipient Party without reliance on information received from the other Party under this
    Agreement, as evidenced by such Receiving Party’s written records;
	 	 	 
	 	(c)	is
    hereafter disclosed to the recipient Party without restriction by a Third Party having a legal right to make such disclosure; or
	 	 	 
	 	(d)	is
    or becomes part of the public domain through no breach of this Agreement by the recipient Party.

 

Section
12.02 Terms of Agreement to be Maintained in Confidence. Subject to the provisions of this Article XII, the Parties agree
that the terms of this Agreement are deemed Confidential Information of both Parties and, except to the extent disclosure is authorized
pursuant to Section 12.03, shall be subject to the restrictions on use and disclosure set forth herein.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 21 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Section
12.03 Required Disclosures. Nothing in this Agreement shall be construed to restrict the Parties from disclosing Confidential
Information as required by Applicable Law or court order or other governmental order or request, provided in each case the Party requested
to make such disclosure shall timely inform the other Party and use all reasonable efforts to limit the disclosure and maintain the confidentiality
of such Confidential Information to the extent possible. In addition, the Party requested to make such disclosure will cooperate with
the other Party to seek to prevent or limit such disclosure by appropriate legal means, to the extent permitted by law and consistent
with any applicable deadlines.

 

Section
12.04 Public Announcements. No public announcement or other disclosure to any Third Party concerning the existence of, terms,
or subject matter of this Agreement shall be made, either directly or indirectly, by any Party to this Agreement, except as may be legally
required or as may be required for recording purposes, without first obtaining the approval of the other Party (not to be unreasonably
withheld or delayed) and agreement upon the nature and text of such announcement or disclosure; provided, that each Party shall
be entitled to disclose this Agreement or its terms (a) as required by Applicable Law, including any disclosure requirements imposed
by a stock exchange or securities regulatory agency, and (b) to such Party’s financial, tax and legal advisors, and to potential
investors, corporate partners or acquirers, in each case provided that such persons or entities have confidentiality obligations at least
as stringent as set forth in this Article XII. The Party desiring to make any legally-required public announcement or other legally-required
disclosure (including those which may be required for recording purposes) shall inform the other Party of the proposed announcement or
disclosure in reasonably sufficient time prior to public release, which shall be at least ten (10) Business Days prior to release of
such proposed announcement or disclosure, and shall provide the other Party with a written copy thereof, in order to allow such other
Party to comment upon such announcement or disclosure. Each Party agrees that it shall cooperate fully with the other with respect to
all disclosures regarding this Agreement to the U.S. Securities Exchange Commission and any other Government Authorities, including requests
for confidential treatment of Confidential Information of either Party included in any such disclosure. Neither Party shall use the name,
trademark, trade name, logo or image of the other Party or its Affiliates in any publicity, press release or other public announcement,
including on any website or public forum, without the prior written consent of the other Party, except as permitted under this Section
12.04.

 

Section
12.05 Publications. Nothing in this Agreement shall prevent either Party from making any scientific publication or public
announcement concerning its Development, Manufacturing, use or Commercialization activities with respect to the Products; provided
that neither Party shall disclose any Confidential Information of the other Party in any such publication or announcement without
obtaining such Party’s prior written consent.

 

Section
12.06 Bankruptcy. All Confidential Information disclosed by one Party to the other Party (including any Confidential Information
developed or created by a Party under this Agreement) shall remain the intellectual property of the disclosing Party. In the event that
a court or other legal or administrative tribunal, directly or through an appointed master, trustee or receiver, assumes partial or complete
control over the assets of a Party to this Agreement based on the insolvency or bankruptcy of such Party, the bankrupt or insolvent Party
shall promptly notify the court or other tribunal (a) that Confidential Information received from the other Party under this Agreement
remains the property of the other Party, and (b) of the confidentiality obligations under this Agreement. In addition, the bankrupt or
insolvent Party shall, to the extent permitted by Applicable Law, take all steps necessary or desirable to maintain the confidentiality
of the other Party’s Confidential Information and to ensure that the court, other tribunal or appointee maintains such information
in confidence in accordance with the terms of this Agreement.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 22 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Article
XIII. 

 

INDEMNIFICATION

 

Section
13.01 Indemnification of JOT. Aquanova shall defend and indemnify JOT and its Affiliates, and their respective directors,
officers, employees, Sublicensees, subcontractors, representatives, agents and counsel, and the successors and assigns of the foregoing
(the “JOT Indemnitees”), from and against any and all Losses in connection with any and all Third Party Claims against
a JOT Indemnitee, arising from or occurring as a result of: (a) the Formulation Development, Development, Manufacture, use or Commercialization
of Product conducted by or on behalf of Aquanova or its Affiliates or their respective Sublicensees or subcontractors, (b) any claim
that the Formulation Development Activities, Development, Manufacture, use or Commercialization of any Product infringes any patent,
copyright, trademark or other intellectual property right of any Third-Party or misappropriates any trade secret of any Third-Party (except
to the extent JOT is required to indemnify Aquanova under Section 13.02), (c) Aquanova’s breach of any representation, warranty
or covenant of this Agreement, (d) the negligence or willful misconduct of Aquanova or any of its Affiliates or their respective Sublicensees
or subcontractors except, in each case, to the extent that JOT is obligated to indemnify Aquanova under Section 13.02 below.

 

Section
13.02 Indemnification of Aquanova. JOT shall defend and indemnify Aquanova and its Affiliates and their respective directors,
officers, employees, Sublicensees, subcontractors, representatives, agents and counsel and the successors and assigns of the foregoing
(the “Aquanova Indemnitees”), from and against any and all Losses in connection with any and all Third Party Claims
against an Aquanova Indemnitee, arising from or occurring as a result of: (a) the Development, Manufacture, use or Commercialization
of Product by or on behalf of JOT or its Affiliates or their respective Sublicensees or subcontractors (b) any claim that the Development,
Manufacture, use or Commercialization of any Product infringes any patent, copyright, trademark or other intellectual property right
of any Third-Party or misappropriates any trade secret of any Third Party, solely to the extent such claim relates to the JOT Compound
in the Product or a Trademark in the Territory, (c) JOT’s breach of any representation, warranty or covenant of this Agreement,
(d) any claim of product liability or damage to person or property or death resulting from the use or consumption of a Product in the
Territory, or (e) the negligence or willful misconduct of JOT or any of its Affiliates or their respective Sublicensees or subcontractors,
except, in each case, to the extent that Aquanova is obligated to indemnify JOT under Section 13.01.

 

Section
13.03 Procedure. All indemnification claims in respect of any JOT Indemnitee or Aquanova Indemnitee seeking indemnity under
Section 13.01 or Section 13.02 (collectively, the “Indemnitees” and each an “Indemnitee”) shall
be made solely by the corresponding Party (the “Indemnified Party”). The Indemnified Party shall give the indemnifying
Party (the “Indemnifying Party”) prompt written notice (an “Indemnification Claim Notice”) of any
Losses or discovery of fact upon which such Indemnified Party intends to base a request for indemnification under Section 13.01 or Section
13.02, provided, that the failure by the Indemnified Party to provide such prompt notice to the Indemnifying Party shall only
be a bar to recovering Losses to the extent that the Indemnifying Party can demonstrate that it was actually prejudiced and directly
damaged by such failure. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such
Loss (to the extent that the nature and amount of such Loss are known at such time). Together with the Indemnification Claim Notice,
the Indemnified Party shall furnish promptly to the Indemnifying Party copies of all notices and documents (including court papers) received
by any Indemnitee in connection with the Third Party Claim. At its option, the Indemnifying Party may assume the defense of any indemnification
claim by giving written notice to the Indemnified Party within thirty (30) days after the Indemnifying Parties receipt of an Indemnification
Claim Notice. The assumption of the defense of an indemnification claim by the Indemnifying Party shall not be construed as an acknowledgement
that the Indemnifying Party is liable to indemnify the Indemnified Party in respect of the indemnification claim, nor shall its constitute
a waiver by the Indemnifying Party of any defense it may assert against the Indemnified Party’s claim for indemnification.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 23 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Section
13.04 Insurance. Each Party shall have and maintain such types and amounts of liability insurance as is normal and customary
in the industry generally for parties similarly situated and shall upon request provide the other Party with a copy of its policies of
insurance in that regard, along with any amendments and revisions thereto.

 

Section
13.05 Limitation of Liability.
EXCEPT WITH RESPECT TO THIRD PARTY CLAIMS UNDER THIS Article XIII OR BREACH OF CONFIDENTIALITY
OBLIGATIONS UNDER Article XII, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT OR PUNITIVE DAMAGES, INCLUDING, LOST PROFITS OR LOST REVENUES, ARISING OUT OF THIS AGREEMENT,
HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY, even if SUCH PARTY has been advised of the possibility
of such damages.

 

Article
XIV. 

 

TERM
AND TERMINATION

 

Section
14.01 Term. Unless this Agreement is terminated earlier in accordance with this Article XIV, the term of this Agreement shall
commence on the Effective Date and shall continue, on a Product-by-Product basis, country-by-country until the expiration of the Royalty
Term with respect to a Product (the “Term” of this Agreement) in every country. Upon expiration of such Royalty Term
and except to the extent a license has already reverted to Aquanova pursuant to Section 14.04, Aquanova shall grant, and hereby grants,
a fully paid-up without any additional consideration, non-exclusive, perpetual, irrevocable license under the Joint Patent Rights to
Manufacture and Commercialize such Product in the Field in such country.

 

Termination
for Material Uncured Breach. Either Party shall have the right to terminate this Agreement in the event the other Party has materially
breached or defaulted in the performance of any of its obligations hereunder, and if such breach or default is not corrected or within
sixty (60) days after the breaching Party receives written notice identifying such breach, or if a cure (other than any payment) is not
possible in such sixty (60) day period, such longer period (not exceeding 120 days) during which the breaching Party is diligently pursuing
a cure. If the Parties cannot agree on a Product Schedule for three Products in a row either Party shall have the right to terminate
this Agreement. For the avoidance of doubt, a Party’s decision to terminate a Clinical Trial pursuant to Section 3.04(c) shall
not be deemed to be a material breach of its obligations hereunder.

 

Section
14.02 Termination for Insolvency; Retention of License. If voluntary or involuntary proceedings by or against a Party are
instituted in bankruptcy under any insolvency law, or a receiver or custodian is appointed for such Party, or proceedings are instituted
by or against such Party for corporate reorganization or the dissolution of such Party, which proceedings, if involuntary, shall not
have been dismissed within ninety (90) days after the date of filing, or if such Party makes an assignment for the benefit of creditors,
or substantially all of the assets of such Party are seized or attached and not released within ninety (90) days thereafter, the other
Party may immediately terminate this Agreement effective upon notice of such termination. Notwithstanding the bankruptcy of a Party,
or the impairment of performance by a Party of its obligations under this Agreement as a result of bankruptcy or insolvency of such Party,
and subject to such other Party’s rights to terminate this Agreement for reasons other than bankruptcy or insolvency as expressly
provided in this Agreement, the other Party shall be entitled to retain the licenses under the terms and conditions granted herein, and
otherwise in accordance with Section 365(n) of the United States Bankruptcy Code.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 24 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Section
14.03 General Effect of Termination.

 

	 	(a)	Accrued
    Obligations. Termination of this Agreement or for any reason shall not release any Party hereto from any liability which,
    at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination,
    nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity which accrued or are
    based upon any event occurring prior to such termination. 
	 	 	 
	 	(b)	Return
    of Materials. Upon any termination of this Agreement, each Party shall promptly return to the other Party all materials,
    Know-How and other tangible Confidential Information received from the other Party (except one copy of which may be retained by legal
    counsel for archival purposes); except that if the Agreement is terminated with respect to a Product only, each Party shall so return
    Confidential Information relating exclusively to the Product. 
	 	 	 
	 	(c)	Reversion
    of Rights. Upon any ending of this Agreement, all licenses granted by a Party to the other Party shall be terminated and
    the rights therein shall revert to the licensor Party; 

 

Section
14.04 Survival. Articles VI, XI, XII, XIII, XIV, XV shall survive the expiration or termination of this Agreement for any
reason. In addition, any other provision required to interpret and enforce the Parties’ rights and obligations under this Agreement
shall also survive, but only to the extent required for the observation and performance of the aforementioned surviving portions of this
Agreement.

 

Article
XV. 

 

MISCELLANEOUS

 

Section
15.01 Governing Law; Equitable Relief.

 

	 	(a)	This
    Agreement, and any claim, dispute, or controversy of whatever nature arising out of or relating to this Agreement shall be governed
    by and construed in accordance with the laws of Germany, without giving effect to any principles, statutory provisions or other rules
    of choice of law that would require the application of the laws of a different state or country. Place of jurisdiction is Frankfurt
    am Main/Germany.
	 	 	 
	 	(b)	No
    provision herein shall be construed as precluding a Party from bringing an action for injunctive relief or other equitable relief
    prior to the initiation or completion of the above procedure. 

 

Section
15.02 Alternative Dispute Resolution. The Parties shall try to settle their differences amicably between themselves. If any
claim, dispute, or controversy of whatever nature arising out of or relating to this Agreement, including the performance or alleged
non-performance of a Party of its obligations under this Agreement arises between the Parties (each a “Dispute”),
a Party shall, before initiating any proceedings pursuant to this Article XV, notify the other Party in writing of such Dispute. If the
Parties are unable to resolve the Dispute within twenty (20) days of receipt of the written notice by the other Party, such dispute shall
be referred to a member of each of the Party’s Chief Executive Officers, who shall meet in person at least once and use their good
faith efforts to resolve the Dispute within thirty (30) days after such referral.

 

Section
15.03 Arbitration. All disputes or controversies that may arise between the Parties in the interpretation or implementation
of this Agreement shall be finally settled by sole arbitration in Geneva, Switzerland in accordance with the Rules of the ICC International
Court of Arbitration (ICC Rules). The arbitration shall be conducted in the English language. The award rendered by arbitrator shall
be final and binding upon the Parties.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 25 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Section
15.04 Waiver. Neither Party may waive or release any of its rights or interests in this Agreement except in writing. The failure
of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute
a waiver of that right or excuse a similar subsequent failure to perform any such term or condition. No waiver by either Party of any
condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or term or of another
condition or term.

 

Section
15.05 Assignment. This Agreement shall not be assignable by either Party without the written consent of the other Party, except
that either Party may assign this Agreement, without such consent, to an Affiliate of such Party. The terms and conditions of this Agreement
shall be binding on and inure to the benefit of the permitted successors and assigns of the Parties.

 

Section
15.06 Notices. Any notices, requests and other communications hereunder shall be in writing and shall be personally delivered
or sent by international express delivery service, registered or certified air mail, return receipt requested, postage prepaid, or by
facsimile (confirmed by prepaid registered or certified air mail letter or by international express delivery mail) (e.g., FedEx)), and
shall be deemed to have been properly served to the addressee upon receipt of such written communication, to the following addresses
of the Parties, or such other address as may be specified in writing to the other Parties hereto:

 

	 	If
    to Aquanova:	Aquanova
    AG
	 	 	Birkenweg
    8-10
	 	 	64295
    Darmstadt
	 	 	Germany
	 	 	 	 
	 	 	Attention:
    Office of the Executive Board
	 	 	Telephone:
    +49 6151 66969-0
	 	 	Email:
    frank.behnam@aquanova.de
	 	 	 	 
	 	If
    to JOT:	Jupiter
    Orphan Therapeutics, Inc.
	 	 	601
    Heritage Drive
	 	 	Jupiter,
    FL 33458
	 	 	 	 
	 	 	Attention:	Office
    of the CEO
	 	 	Telephone:	+1
    561 308-7780
	 	 	Email:	c.rosen@jupiterorphan.com

 

Section
15.07 Force Majeure. Neither Party shall be liable to the other for failure or delay in the performance of any of its obligations
under this Agreement for the time and to the extent such failure or delay is caused by earthquake, riot, civil commotion, terrorism,
war, hostilities between nations, governmental law, order or regulation, embargo, action by the government or any agency thereof, act
of God, storm, fire, accident, labor dispute or strike, sabotage, explosion or other similar or different contingencies, in each case,
beyond the reasonable control of the respective Party. The Party affected by force majeure shall provide the other Party with full particulars
thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with
its activities), and will use its best endeavors to overcome the difficulties created thereby and to resume performance of its obligations
as soon as practicable. If the performance of any obligation under this Agreement is delayed owing to a force majeure for any continuous
period of more than six (6) months, the Parties hereto shall consult with respect to an equitable solution including the possible termination
of this Agreement.

 

Section
15.08 Independent Contractors. Nothing contained in this Agreement is intended implicitly, or is to be construed, to constitute
JOT or Aquanova as partners or joint ventures in the legal sense. No Party hereto shall have any express or implied right or authority
to assume or create any obligations on behalf of or in the name of any other Party or to bind any other Party to any contract, agreement
or undertaking with any Third Party.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 26 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Section
15.09 Severability. If any of the terms or provisions of this Agreement are in conflict with any applicable statute or rule
of law, then such terms or provisions shall be deemed inoperative to the extent that they may conflict therewith and shall be deemed
to be modified to conform to such statute or rule of law. In the event that the terms and conditions of this Agreement are materially
altered as a result of the above, the Parties will renegotiate the terms and conditions of this Agreement to resolve any inequities.

 

Section
15.10 Further Assurances. At any time or from time to time on and after the date of this Agreement, either Party shall at
the request of the other Party (i) deliver to the requesting Party such records, data or other documents consistent with the provisions
of this Agreement, (ii) execute, and deliver or cause to be delivered, all such consents, documents or further instruments of assignment,
transfer or license, and (iii) take or cause to be taken all such actions, as the requesting Party may reasonably deem necessary or desirable
in order for the requesting Party to obtain the full benefits of this Agreement and the transactions contemplated hereby.

 

Section
15.11 Entire Agreement; Amendments. This Agreement, together with the Exhibits and the Product Schedules, constitute the entire
agreement, both written and oral, with respect to the subject matter hereof, and supersedes and terminates all prior or contemporaneous
understandings or agreements, whether written or oral, between JOT and Aquanova with respect to such subject matter. Any amendment, modification
or supplement of or to any provision of this Agreement, including the Exhibits hereto or any Product Schedule, shall be effective only
in a writing and signed by a duly authorized officer of suitable title of the Parties hereto.

 

Section
15.12 Headings. The captions to the Articles and Sections hereof are not a part of this Agreement, but are included merely
for convenience of reference only and shall not affect its meaning or interpretation.

 

Section
15.13 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original
and all of which together shall constitute one and the same instrument.

 

Section
15.14 Interpretation. Unless the context of this Agreement otherwise requires: (a) words of any gender include each other
gender; (b) words using the singular or plural number also include the plural or singular number, respectively; (c) the terms “hereof,”
“herein,” “hereby,” and derivative or similar words refer to this entire Agreement; (d) the terms “Article”,
“Section” or “Exhibit” refer to the specified Article, Section or Exhibit of this Agreement; (e) the term “including”
means “including without limitation” or “including but not limited to”; and (f) “days” refers to
calendar days unless otherwise specified as a “Business Day”. All accounting terms used but not otherwise defined herein
shall have the meanings ascribed to such terms under the applicable Accounting Standards as applied to a Party. All references to “$”
amounts hereunder shall be deemed to be U.S. Dollars, and all payments due hereunder shall be made in U.S. Dollars.

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 27 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

IN
WITNESS WHEREOF, the Parties hereto have caused this Master Development and License Agreement to be duly executed by their authorized
representatives effective as of the Effective Date.

 

	AQUANOVA
    AG	 	JUPITER
    ORPHAN THERAPEUTICS, INC.
	 	 	 	 	 
	By:	 /s/
    Frank Behnam 	 	By:	 /s/
    Christer Rosen 
	Name:	Frank
    Behnam	 	Name:	Christer
    Rosen
	Title:	Member
    of the Executive Board	 	Title:	Chief
    Executive Officer

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 28 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
1: Active Ingredient specification

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 29 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
1: Active Ingredient specification (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 30 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
1: Active Ingredient specification (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 31 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
1: Active Ingredient specification (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 32 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
1: Active Ingredient specification (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 33 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
1: Active Ingredient specification (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 34 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
1: Active Ingredient specification (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 35 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
1: Active Ingredient specification (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 36 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
2: Formulation of Active Ingredient

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 37 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
2: Formulation of Active Ingredient (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 38 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
2: Formulation of Active Ingredient (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 39 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights

 

 

 

Appendix
3: Joint Patent Rights (continued)

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 40 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 41 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 42 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 43 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 44 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 45 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 46 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 47 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 48 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 49 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 50 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 51 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 52 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 53 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 54 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 55 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 56 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 57 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 58 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
3: Joint Patent Rights (continued)

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 59 of 60
	(version as per September13th, 2016) / confidential	 

     

    

 

Appendix
4: German Utility model DE 20 2009 016 292 U1

 

 

    	DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT	page 60 of 60
	(version as per September13th, 2016) / confidential

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]